EX-10.5



 Exhibit 10.5 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH 

“[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE 

SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN 

APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 

PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

EXCLUSIVE LICENSE AGREEMENT 
 This
Exclusive License Agreement (this “Agreement”) is made effective as of November 4, 2016 (the “Effective Date”) between: 

UNIVERSITY HEALTH NETWORK, an Ontario corporation incorporated by special statute under the University Health Network Act,
1997, having a principal office at 190 Elizabeth Street, R. Fraser Elliott Building—Room 1S-417, Toronto, Ontario M5G 2C4 (“UHN”) 

-AND- 
 AvroBio,
Inc., a Delaware corporation, with offices at 400 Technology Square, 10th Floor, Cambridge, MA 02139 (“Avro”) 

In this Agreement, UHN and Avro may be referred to individually as a “Party”, or collectively as the “Parties”. 

BACKGROUND: 
 UHN principal investigator Dr. Jeffrey
Medin (the “Principal Investigator”; as further defined below) has created, conceived or developed compositions and methods for use in the treatment of Fabry disease. 

UHN owns and controls certain intellectual property rights relating to the treatment of Fabry disease. 

Avro wishes to license from UHN rights under such intellectual property rights so as to allow Avro to research, develop, manufacture and commercialize
products in accordance with the following terms and conditions. 
 UHN and Avro entered into an option agreement, dated as of January 27, 2016,
pursuant to which UHN exclusively optioned to Avro the right to exclusively license all UHN owned or controlled intellectual property rights relating to UHN developed compositions and methods for use in the treatment of Fabry disease (the
“Option Agreement”). 
 The parties wish to enter into this Agreement in accordance with the terms and conditions set forth herein. 

ARTICLE 1 - INTERPRETATION 
  

	1.1	Defined Terms. For the purposes of this Agreement, the following terms shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:


  

	 	1.1.1	“Affiliate” means, with respect to any Person, a Person directly or indirectly controlled by, controlling, or under common control with such Person. For the purposes of this definition,
except as otherwise expressly set out in this Agreement, “control” means (a) direct or indirect beneficial ownership of at least fifty percent (50%) of the voting stock of such Person or (b) with the power to direct the
management and policies of such entities. 









	 	1.1.2	“Agreement” means this Exclusive License Agreement, and all of its Schedules, and the terms “herein”, “hereunder”, “hereto” and such similar expressions shall
refer to this Agreement. 

  

	 	1.1.3	“Avro Insurance” shall have the meaning provided in Section 13.1. 

  

	 	1.1.4	“Calendar Year” means each twelve (12) month period beginning on January 1 and each subsequent anniversary thereof; provided, however, that (a) the first Calendar Year of
this Agreement will commence on the Effective Date and end on December 31 of the same year, and (b) the last Calendar Year of this Agreement will commence on January 1 of the Calendar Year in which this Agreement terminates or expires
and end on the date of expiration or termination of this Agreement. 

  

	 	1.1.5	“Claims” shall have the meaning provided in Section 12.1. 

  

	 	1.1.6	“Clinical Trial Application” or “CTA” has the meaning accorded this term in accordance with the requirements of Health Canada, including all amendments and
supplements to such application, or any IND or other equivalent filing with any other Regulatory Authority. 

  

	 	1.1.7	“Clinical Trial Data” means all Patient Data generated from the one or more of the clinical trial sites (including UHN, Calgary and Halifax), but excludes Sample Processing Data. For
greater certainty, investigator suspected adverse events are not separately identified within the Clinical Trial Data, but are reviewed in accordance with the Clinical Trial Protocol and reported to Avro in accordance with obligations as outlined in
Sections 2.4.4 to 2.4.6. 

  

	 	1.1.8	“Clinical Trial Protocol” means the protocol governing the UHN Planned Trial. The Clinical Trial Protocol may be amended from time to time by agreement of the Parties subject to funding
being available to support the costs of changes as required by the amendment. 

  

	 	1.1.9	“Combination Product” means a Licensed Product sold or used in combination with one or more other products which are not Licensed Products. 


 

	 	1.1.10	 “Confidential Information” of a Party means any and all confidential or
proprietary information of and disclosed by or on behalf of a Party and/or any of its Affiliates (a “Disclosing Party”) which has or does come into the possession or knowledge of the other Party and/or any of its Affiliates
(a “Receiving Party”) in connection with or as a result of entering into this Agreement and which is (a) marked as confidential or identified as confidential at the time of disclosure, or (b) given the nature of the
information or circumstances of disclosure, would be recognized as confidential or proprietary by a reasonable person, in each case including information concerning the Disclosing Party’s past, present and future business, research and
development, technology, customers and suppliers. 



  
 *** Confidential Treatment
Requested *** 
  
 2 









	 	
Information shall not be considered “Confidential Information” to the extent that the information: 


(a) is part of the public domain at the time of disclosure, 

(b) subsequently becomes part of the public domain through no act or fault of the Receiving Party or its Representatives in violation of this
Agreement, 
 (c) can be demonstrated by the Receiving Party’s written records or other credible evidence to have been known or
otherwise 
 (d) available to the Receiving Party prior to the disclosure by the Disclosing Party, 

(e) can be demonstrated by the Receiving Party’s written records or other credible evidence, to have been provided to the Receiving
Party, without restriction, by a Third Party who is not under a duty of confidentiality respecting the information disclosed, 
 (f) can be
demonstrated by the Receiving Party’s written records, or other credible evidence, to have been independently developed by or on behalf of the Receiving Party without use of or reference to the disclosed Confidential Information, or 

(g) is identified in writing by the Disclosing Party as no longer constituting Confidential information. 

 

	 	1.1.11	“Disclosing Party” shall have the meaning provided in Section 1.1.10. 

  

	 	1.1.12	“Exclusively Licensed Know-How” means (a) any and all Fabry Know-How, (b) any and all Licensed
Trial Related Data, and (c) the Clinical Trial Protocol. 

  

	 	1.1.13	“Fabry Know-How” means any and all Know-How (A) existing as of the Effective Date that (i) was
created, conceived or developed by (1) the Principal Investigator; (2) by UHN employees or agents under the direction or supervision of the Principal Investigator, or (3) the UHN CRO; (ii) is owned or controlled by UHN and
(iii) is listed or otherwise defined in Schedule “A”, or Schedule “B”, or (B) existing as of the Effective Date or during the Term that was (i) created, conceived or developed by one or more third party(ies) in
collaboration with UHN or the Principal Investigator (or UHN employees or agents of UHN under the direction or supervision of the Principal Investigator) in connection with the UHN Planned Trial and for which UHN has been granted exclusive rights
pursuant to a Fabry Trial Team Agreement. In the event that there exists as of the Effective Date other Know-How which is (a) relevant to the Field of Use, (b) created, conceived or developed by
(1) the Principal Investigator, (2) by UHN employees or agents under the direction or supervision of the Principal Investigator, or (3) the UHN CRO, and (c) owned or controlled by UHN and is not Improved Therapies Know-How, the Parties will update Schedule A and/or Schedule B accordingly. For greater certainty Fabry Know-How does not include Fabry Patents, Improved Therapies Patents or
Improvement Patents or any Patent Rights in the SRA Intellectual Property. 


  
 *** Confidential Treatment
Requested *** 
  
 3 









	 	1.1.14	“Fabry Non-Exclusive Know-How” means any and all Know-How existing
as of the Effective Date or during the Term that was created, conceived or developed by one or more third party(ies) in collaboration with the Principal Investigator (or UHN employees or agents of UHN under the direction or supervision of the
Principal Investigator) in connection with the UHN Planned Trial and for which UHN has been granted non-exclusive rights pursuant to a Fabry Trial Team Agreement. 


 

	 	1.1.15	“Fabry Patents” means (a) the patents and patent applications listed on Schedule “C”, (b) any Canadian or U.S. or other foreign patent application corresponding or claiming
priority to the patents and applications listed in Schedule “C”, and all patents issuing therefrom, (c) all divisionals, continuations and continuations-in part applications to the patents and
applications listed in Schedule “C”, and all patents issuing therefrom, with the proviso that any continuations-in-part applications and/or patents shall only
apply to claims that are directed to subject matter specifically described in any patent or patent application described in clauses (a) or (b); (d) all foreign counterparts of any of the patents or applications in clauses (a), (b), and (c)
(including, without limitation, any European Supplementary Protection Certificates or equivalents), and all patents issuing therefrom; and (e) all patents of addition, reissues, renewals, and/or extensions of any of the patents or patent
applications set out in any of clauses (a), (b), (c), or (d), but excluding any patents or patent applications listed as “Excluded Patents” on Schedule C. 


 

	 	1.1.16	“Fabry Vector” means the Lentiviral a-Gal A expression vector utilized in the UHN Planned Trial. 


 

	 	1.1.17	“Fabry Trial Team” means the principal investigators in their appointment and capacity as investigators of their respective Fabry Trial Team Institution(s). 


 

	 	1.1.18	“Fabry Trial Team Institution(s)” means each of the institutions involved in the UHN Planned Trial. As of the Effective Date, the Fabry Trial Team Institutions include Hamilton
Regional Laboratory Medicine Program (“Hamilton Service”), Hamilton Health Sciences Corporation (“Hamilton Clinical”), Universite de Sherbrooke (“Sherbrooke”), The Governors of the University of Calgary in conjunction
with Alberta Health Services (collectively “Calgary”), London Health Sciences Centre (“London”), and Nova Scotia Health Authority (“Halifax”). The list of Fabry Trial Team Institutions(s) may be amended by agreement of
the Parties. 

  

	 	1.1.19	“Fabry Trial Team Agreement(s)” means any agreement(s) to be entered into between Fabry Trial Team Institutions, UHN, and Avro governing, among other items, the transfer of certain
Exclusively Licensed Know-How and Non-Exclusively Licensed Know-How from the Fabry Trial Team Institutions to UHN and Avro. The
Fabry Trial Team Agreement(s) may be amended from time to time by agreement of the Parties. 

  

	 	1.1.20	“FDA” means the United States Food and Drug Administration and any successor agency thereto. 

  

	 	1.1.21	“Field of Use” means Fabry disease. 


  
 *** Confidential Treatment
Requested *** 
  
 4 









	 	1.1.22	“First Commercial Sale” means, with respect to a Licensed Product and a country, the first arms-length commercial sale for monetary value of such Licensed Product to a Third Party in such
country after Regulatory Approval allowing for the marketing and sale of such Licensed Product has been obtained in such country. Sales prior to receipt of Regulatory Approval for such Licensed Product, such as
so-called “treatment IND sales,” “named patient sales”, “Health Canada Special Access Programme sales” and “compassionate use sales” shall not be construed as a First
Commercial Sale. 

  

	 	1.1.23	“Gross Revenue” means the gross amount received by each of: (a) Avro and/or its Affiliates, and (b) any permitted Sublicensee, where such gross amount is received in respect of
the sale or transfer or other disposition of a Licensed Product to a Third Party. 

  

	 	1.1.24	“IL-12 Agreement” means the Exclusive License Agreement, dated January 27, 2016, by and between Avro and UHN (and as further amended or
restated from time to time). 

  

	 	1.1.25	“Improvements” means any and all discoveries, derivatives, adaptations, changes, inventions, enhancements and modifications (whether patentable or not) of the Fabry Patents or Fabry Know-How that are created, conceived, developed or reduced to practice either (a) prior to the Effective Date or during the Option Term, by (i) the Principal Investigator (ii) any employees or agents
of UHN under the direction or supervision of the Principal Investigator or (iii) the UHN CRO, where same are owned or controlled by UHN and relevant to the Field of Use, or (b) arising from the UHN Planned Trial; but, in each case
((a)-(b)), are not (i) Improved Therapies or (ii) in connection with or in performance of an SRA. 

  

	 	1.1.26	“Improved Therapies” means any and all discoveries, derivatives, adaptations, changes, inventions, enhancements or modifications (whether patentable or not) of the Fabry Patents or Fabry Know-How that are created, conceived, developed or reduced to practice prior to the Effective Date or during the Option Term by the Principal Investigator (or any employees or agents of UHN under the direction or
supervision of the Principal Investigator) and relevant to the Field of Use, where the technology advancement relates to a new product or a method relating thereto which is distinct from the technology encompassed by the UHN Planned Trial and
requires the submission of a new IND or foreign equivalent thereof. For clarity, addition of TMPK to the Fabry Vector is NOT considered a new product. 

  

	 	1.1.27	“Improved Therapies Know-How” means any and all Know-How that exists within any of the Improved Therapies.


  

	 	1.1.28	“Improved Therapies Patents” means any and all Patent Rights that claim or cover any of the Improved Therapies. 


 

	 	1.1.29	“Improvements Know-How” means any and all Know-How that exists within any of the Improvements.


  

	 	1.1.30	“Improvements Patents” means Patent Rights that claim or cover any of the Improvements. 


  
 *** Confidential Treatment
Requested *** 
  
 5 









	 	1.1.31	“IND” means with respect to a product, an Investigational New Drug Application filed with the FDA with respect to such product pursuant to 21 C.F.R. § 312 before the commencement of
human clinical trials involving such product. 

  

	 	1.1.32	“Know-How” means any and all commercial, technical, regulatory, scientific and other know-how, information,
knowledge, technology, methods, processes, practices, standard operating procedures, formulae, instructions, skills, techniques, procedures, assay protocols, experiences, ideas, technical assistance, designs, drawings, assembly procedures,
specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, regulatory, manufacturing and quality
control data and know-how, including study designs and protocols), in all cases now known or hereafter developed, whether or not confidential or proprietary, in written, electronic or any other form. Know-How shall exclude Patent Rights (including rights in the Fabry Patents, Improved Therapies Patents, and Improvement Patents). 


 

	 	1.1.33	“License” shall have the meaning provided in Section 2.1. 

  

	 	1.1.34	“Licensed Patents” means: (a) any and all Fabry Patents, (b) any and all Optioned Improvement Patents, and (b) any and all Patent Rights within the Licensed SRA IP.


  

	 	1.1.35	“Licensed Product” means any product in the Field of Use that (a) the manufacture, use or sale of which, but for the licenses granted herein, would infringe a Valid Claim in the
Licensed Patents, or (b) incorporates, uses, or practices the Exclusively Licensed Know-How or Non-Exclusively Licensed
Know-How. For greater certainty and clarity, a product in the Field of Use that (i) incorporates, uses or practices any preclinical data or clinical data within the Exclusively Licensed Know-How or Non-Exclusively Licensed Know-How, or (ii) [***] shall be considered a Licensed Product. 


 

	 	1.1.36	“Licensed SRA IP” means any and all SRA IP for which the Parties have agreed to incorporate such SRA IP into this Agreement per Section 3.1 (as such IP is further listed in Schedule
“D” (as may be amended from time to time)). 

  

	 	1.1.37	“Licensed Technology” means any and all Licensed Patents, Exclusively Licensed Know-How and Non-Exclusively
Licensed Know-How. 

  

	 	1.1.38	“License Transfer Fee” shall have the meaning provided in Section 16.4.2. 

  

	 	1.1.39	“Licensed Trial Related Data” means any and all information, data, results and reports (i) owned and controlled by UHN, or (ii) for which UHN has been granted rights and/or
permission pursuant to a Fabry Trial Team Agreement and (ii) relating to the UHN Planned Trial, including Patient Data, regulatory documents (including Clinical Trial Applications, Q&As, investigator brochures), manufacturing data
(including supplier agreements and batch records) and such other relevant data relating to the use of the Licensed Products in the conduct of the UHN Planned Trial. 


  
 *** Confidential Treatment
Requested *** 
  
 6 









	 	1.1.40	“Net Revenues” means, the Gross Revenue net of any of the following: 


(a) normal, customary and actual quantity, trade or cash allowance/discounts, credits or volume discounts, and other price reductions with
respect to Licensed Products; 
 (b) credits, rebates or allowances because of billing errors, damaged, outdated, obsolete, nonconforming,
rejected, re-worked or recalled goods or services or returns with respect to Licensed Product(s); 

(c) freight, postage, shipping and insurance charges incurred in transporting the Licensed Product(s) to the Third Party or its designee; and

 (d) taxes including sales, use, value-added, and other direct taxes, customs, duties, tariffs, surcharges, or other governmental charges
(other than income taxes) levied on, absorbed or otherwise imposed on sales of Licensed Product(s); 
 with (a) - (d) to be as determined
from the books and records of Avro and/or its Affiliate(s) and/or permitted Sublicensee(s), maintained in accordance with generally accepted accounting principles. 

For the avoidance of doubt, transfers of a Licensed Product between any of Avro, an Affiliate or a Sublicensee for sale by the
transferee shall not be considered Net Revenues hereunder. Net Sales shall not include transfers or dispositions for charitable, promotional, preclinical, clinical, regulatory, or governmental purposes. 

In the event that a Licensed Product is sold as a Combination Product, Net Revenues, for the purposes of determining royalty
payments on the Combination Product, means the gross amount collected for the Combination Product less the deductions set forth in clauses (a)—(d) above, multiplied by a proration factor that is determined as follows: 

If all components of the Combination Product were sold separately during the same or immediately preceding Quarterly Period,
the proration factor shall be determined by the formula [A / (A+B)], where A is the average gross sales price of all Licensed Product components (as applicable) during such period when sold separately from the other component(s), and B is the
average gross sales price of the other component(s) during such period when sold separately from the Licensed Product components (as applicable); or 

If all components of the Combination Product were not sold or provided separately during the same or immediately preceding
Quarterly Period, the proration factor shall be determined by the Parties in good faith negotiations based on the reasonably estimated commercial value or relative value contributed by each component. 

 

	 	1.1.41	“Non-Exclusively Licensed Know-How” means (a) Fabry
Non-Exclusive Know-How (b) any and all Improvements Know-How, and (c) any and all
Know-How within the Licensed SRA IP. 

  

	 	1.1.42	“Notice(s)” shall have the meaning provided in Section 15.1. 


  
 *** Confidential Treatment
Requested *** 
  
 7 









	 	1.1.43	“Option Term” means the period commencing on the Effective Date and ending on the [***] anniversary thereof, unless extended by the Parties in writing. 


 

	 	1.1.44	“Optioned Improvements Patents” means any and all Improvement Patents which the Parties have agreed to incorporate into this Agreement per Section 3.2.1, as further listed in Schedule
“E” (or as may be amended from time to time). 

  

	 	1.1.45	“Patent Rights” means all rights in, to and under any patent applications or patents, whether domestic or foreign, or any equivalent thereof, including all direct or indirect divisionals,
continuations, continuations-in-part, reissues, reexaminations, supplemental protection certificates or extensions thereof, and any patent that issues on any of the
foregoing. 

  

	 	1.1.46	“Patient Data” means any and all anonymized and de-identified clinical data, information, results and reports arising from the performance of the
UHN Planned Trial (including, for clarity, all raw data, cleaned data, final data, data summaries, ‘Case Report Forms’ or such similar documents for the UHN Planned Trial). 


 

	 	1.1.47	“Person” includes any individual, corporation or other incorporated organization, sole proprietorship, partnership, unincorporated association, unincorporated syndicate, unincorporated
organization, trust, body corporate and a natural person in his or her capacity as trustee, executor, administrator or other legal representative. 

  

	 	1.1.48	“Phase 1 Clinical Trial” means a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations.


  

	 	1.1.49	“Phase 2 Clinical Trial” means a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. 312.21(b) or corresponding foreign regulations.


  

	 	1.1.50	“Phase 3 Clinical Trial” means a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. 312.21(c) or corresponding foreign regulations.


  

	 	1.1.51	“Phase 2/3 Clinical Trial” means a human clinical trial of a Licensed Product that is not a Phase 2 Clinical Trial or a Phase 3 Clinical Trial, but some combination thereof.


  

	 	1.1.52	“Pivotal Trial” means, with respect to any Licensed Product, a clinical trial that at the time of commencement, is intended by Avro to be the basis for Regulatory Approval with respect to
clinical trials for such Licensed Product. 

  

	 	1.1.53	“Principal Investigator” shall mean Dr. Jeffrey Medin in his appointment and capacity as affiliate scientist. For purposes of clarity, Dr. Medin shall not be considered a
Principal Investigator under this Agreement as it pertains to his appointment and scientific research activities at the Medical College of Wisconsin. 


  
 *** Confidential Treatment
Requested *** 
  
 8 









	 	1.1.54	“Quarterly Period” means each successive three (3) calendar month period during the Term ending March 31, June 30, September 30 and December 31. The first and last
Quarterly Periods may be less than three (3) calendar months and will commence on the Effective Date of this Agreement and terminate on the date this Agreement expires or is earlier terminated, respectively. 


 

	 	1.1.55	“Receiving Party” shall have the meaning provided in Section 1.1.10. 

  

	 	1.1.56	“Regulatory Approval” means those clearances or approvals of a Regulatory Authority, with respect to any jurisdiction, that are legally required for the marketing or sale of Licensed
Products in such jurisdiction. 

  

	 	1.1.57	“Regulatory Authority” means any applicable government regulatory authority involved in granting clearances or approvals for the manufacturing or marketing of a Licensed Product,
including, in the United States, the FDA, and in Canada, Health Canada. 

  

	 	1.1.58	“Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any regulatory authority with respect to a Licensed Product other than patents,
including, without limitation, rights conferred in the United States under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), orphan drug exclusivity, rights conferred in Canada under the Patented Medicines
(Notice of Compliance) Regulation, the data protection provisions contained in the Food and Drug Regulations (Canada) or rights similar thereto outside the United States or Canada. 


 

	 	1.1.59	“Regulatory Filing” means any documentation comprising or relating to or supporting any filing or application with any Regulatory Authority with respect to the UHN Planned Trial, including
any documents submitted to any Regulatory Authority and all supporting data, including CTAs and INDs, and all correspondence with any Regulatory Authority with respect to the UHN Planned Trial (including minutes of any meetings, telephone
conferences or discussions with any Regulatory Authority). 

  

	 	1.1.60	“Representatives” shall have the meaning provided in Section 9.1. 

  

	 	1.1.61	“Reviewed Sample Processing Data” means Sample Processing Data which UHN and/or UHN CRO have had in their possession for [***], irrespective of whether UHN Principal Investigator has
reviewed such data. For greater certainty, the intent is that all Sample Processing Data is being sent by the Fabry Trial Team Institutions to UHN and UHN Principal Investigator concurrently. For greater certainty, investigator suspected adverse
events are not separately identified within the Reviewed Sample Processing Data, but are reviewed in accordance with the Clinical Trial Protocol and reported to Avro in accordance with obligations as outlined in Sections 2.4.4 to 2.4.6.


  

	 	1.1.62	“Royalties” shall have the meaning provided in Section 4.5. 

  

	 	1.1.63	 “Royalty Term” means, on a Licensed Product-by-Licensed Product basis, the period commencing on the First Commercial Sale of the Licensed Product and continuing on a
country-by-country basis as to each Licensed Product until the 



  
 *** Confidential Treatment
Requested *** 
  
 9 









	 	
later of (a) the expiration or termination of the last to expire Valid Claim within the Licensed Technology that covers such Licensed Product in such country, or (b) expiration of
Regulatory Exclusivity for such Licensed Product in such country, or (c) ten (10) years from the date of First Commercial Sale of such Licensed Product in such country. 


 

	 	1.1.64	“Sample Processing Data” means all Patient Data generated from testing patient samples by or on behalf of UHN in connection with the UHN Planned Trial and pursuant to the Clinical Trial
Protocol. 

  

	 	1.1.65	“Series A Financing” means Avro’s Series A financing dated as of July 21, 2016. 

  

	 	1.1.66	“Series B Financing” shall be Avro’s next round of financing after the Series A Financing. 

  

	 	1.1.67	“Sponsored Research Agreement” or “SRA” means an agreement between UHN and Avro, by which Avro provides financial support to conduct specific and defined research
at UHN that relates to the Field of Use, and the Parties agree is intended to fall under this Agreement. Sponsored Research Agreements will include the research activities to be conducted, a budget for the conduct of the research activities, the UHN
investigator under whose direction or supervision the research is to be conducted (“SRA Investigator”), and appropriate UHN overhead charges per UHN policies and practices (which may be subject to a reduced overhead rate for
UHN “spin-out” companies per UHN policy and practice). 

  

	 	1.1.68	“SRA Intellectual Property” or “SRA IP” means any and all inventions, improvements, discoveries, and Know-How that are
created, conceived, developed or reduced to practice in connection with or in performance of an SRA by the SRA Investigator or one or more employees or agents of UHN under the direction or supervision of the SRA Investigator, and any Patent Rights,
copyrights or other intellectual property rights related thereto. 

  

	 	1.1.69	“Sublicensee(s)” means any non-Affiliate sublicensee of the rights granted by Avro pursuant to Section 2.3. 


 

	 	1.1.70	“Sublicensing Revenue” means, all consideration received by Avro or its Affiliate(s) from Sublicensees in consideration for sublicensing of Licensed Technology to such Sublicensees by Avro
or its Affiliate(s), but excluding (a) amounts for research, development, or commercialization activities with respect to the Licensed Products or Licensed Technology (including, without limitation, payment for FTEs), (b) any loans, equity or
debt investments in Avro or its Affiliates, (c) payments by Sublicensees for payment or reimbursement of patent filing, prosecution, defense, enforcement and maintenance and other related expenses, and (d) monies received as flow through
royalty payments pursuant to Section 4.5. Notwithstanding the foregoing, exclusions under any of (a) and (b) are only excluded to the extent such remuneration is a bona fide payment in respect of such matters, and is not being made in
order to reallocate what is otherwise intended to be upfront payments, milestones and royalties. For clarity, a License Transfer Fee shall not be deemed to be Sublicensing Revenue. 


  
 *** Confidential Treatment
Requested *** 
  
 10 









	 	1.1.71	“Sublicensing Fee” shall have the meaning provided in Section 4.6. 

  

	 	1.1.72	“Term” shall have the meaning provided in Section 11.1. 

  

	 	1.1.73	“Territory” means the world. 

  

	 	1.1.74	“Third Party” means a Person other than a Party or its Affiliates. 

  

	 	1.1.75	“TMPK” [***]. 

  

	 	1.1.76	“UHN CRO” means a contract research organization acting on behalf of UHN for purposes of providing management services for the UHN Planned Trial. As of the Effective Date, the UHN CRO is
Ozmosis Research Inc. (“Ozmosis”). 

  

	 	1.1.77	“UHN Indemnitees” shall have the meaning provided in Section 12.1. 

  

	 	1.1.78	“UHN Planned Trial” is the Phase 1 Clinical Trial entitled Clinical Pilot Study of Autologous Stem Cell Transplantation of CD34+ Cells Engineered to Express Alpha-Galactosidase A in
Patients with Fabry Disease and is conducted under the direction or supervision of the Principal Investigator. For purposes of this Agreement, the UHN Planned Trial is currently described in the Clinical Trial Protocol as a clinical trial that will
enroll and dose six (6) patients and will consist of four phases, the screening phase, the pre-treatment phase, the treatment phase and a five year follow-up phase.


  

	 	1.1.79	“Valid Claim” means, on a country-by-country basis, (a) a claim of an issued and unexpired patent which
has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn, abandoned or finally disallowed
without the possibility of appeal or refiling of such application, or (ii) (A) pending for more than [***] since such claim was first presented or (B) is the result of amending another claim pending for more than [***] (either in the same
application or in another application in the same jurisdiction) so as to add or delete an obvious limitation, so as to make a trivial or nonsubstantive change, or so as to change a matter of form; except that any claim that becomes invalid pursuant
to (ii)(A), or (ii)(B), and later issues, shall be considered a Valid Claim from the date of issuance. 

  

	 	1.1.80	Other Defined Terms. All other defined terms in this Agreement shall have the meanings as otherwise specifically set out within the body of this Agreement. 


 

	1.2	Sections and Headings. The division of this Agreement into Articles, Sections and Subsections and the insertion of headings are for reference purposes only and shall not affect the interpretation of this
Agreement. Unless otherwise indicated, any reference to a particular Article, Section, clause or Schedule refers to the specified Article, Section or clause of, or Schedule to, this Agreement. 


  
 *** Confidential Treatment
Requested *** 
  
 11 









	1.3	Number, Gender and Persons. In this Agreement, words importing the singular number shall include the plural and vice versa, words importing gender shall include all genders and words importing persons
shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities. 


 

	1.4	Currency. All monetary amounts in this Agreement are in Canadian funds. 

  

	1.5	Schedules. The following Schedules are annexed to and form part of this Agreement: 


Schedule “A” and Schedule “B” Fabry Know-How (as may be updated from time to time
as dictated herein) 
 Schedule “C” - Fabry Patents (as may be updated from time to time) 

Schedule “D” - Licensed SRA IP (as may be updated from time to time) Schedule “E”—Optioned Improvement Patents (as may
be updated from time to time). 
  

	1.6	Accounting Principles. Any reference in this Agreement to “generally accepted accounting principles” refers to generally accepted accounting principles as approved from time to time by the Canadian
Institute of Chartered Accountants or any successor institute, U.S. generally accepted accounting principles, or International Financial Reporting Standards. 

  

	1.7	Best of Knowledge. “To the best of the knowledge” or “to the knowledge”, unless otherwise qualified hereunder means a statement of the declaring Party’s knowledge of the actual facts or
circumstances to which such phrase relates without having made any inquiries or investigations in connection with such facts and/or circumstances. 


ARTICLE 2 - GRANT OF RIGHTS 
  

	2.1	License Grant. UHN hereby grants to Avro and its Affiliates during the Term (collectively, the “License”). 

  

	 	2.1.1	an exclusive (subject to Section 2.2), royalty-bearing, transferable (as set forth in Section 16.4) license, with the further right to grant sublicenses subject to Section 2.3, under the
Exclusively Licensed Know-How and Licensed Patents, to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have
imported, export and have exported Licensed Products in the Field of Use for the Territory. 

  

	 	2.1.2	a non-exclusive, royalty-bearing, transferable (as set forth in Section 16.4) license, with the further right to grant sublicenses subject to Section 2.3, under
the Non-Exclusively Licensed Know-How, to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have
offered for sale, import, have imported, export and have exported Licensed Products in the Field of Use for the Territory. 

  

	2.2	UHN Retention of Rights. 

  

	 	2.2.1	 The License granted to Avro under Section 2.1 is subject to UHN’s retention of its rights to use
the Licensed Technology without charge, for (a) the conduct of the 



  
 *** Confidential Treatment
Requested *** 
  
 12 









	 	
UHN Planned Trial, (b) research conducted for noncommercial or academic purposes, (c) clinical trials of an academic or noncommercial nature, and (d) the right to grant non-exclusive licenses to Third Party non-profit academic or research institutes for the same purposes of items (a), (b) and (c), and subject to the terms and conditions
outlined in Sections 3.2.1, and 3.2.2, and Articles 9 and 10. 

 In addition, UHN is responsible for conducting the UHN
Planned Trial, and will (itself or with collaborating institutions) enroll and dose at least [***] patients in the UHN Planned Trial with a [***] follow-up phase pursuant to its retained rights and subject to
Section 2.4; provided, however, that UHN shall not be deemed to be in breach of the foregoing obligation in the event that UHN discontinues the UHN Planned Trial due to events outside of the reasonable control of UHN (i.e., actions taken by
Regulatory Authorities, due to a material safety issue of a Licensed Product, or due to Avro’s uncured breach of its payment obligations in the Letter Agreement). In the event that UHN (i) does not enroll or dose any of the [***] patients
in the UHN Planned Trial, (ii) does not complete the [***] follow-up phase for any such patients in the UHN Planned Trial, or (iii) otherwise discontinues or winds down the UHN Planned Trial for any
reason, then UHN will promptly (and in any event within [***]) refund to Avro all monies paid in advance by Avro to UHN pursuant to the Letter Agreement for services or activities not performed (if any), other than any reasonable, non-cancellable Trial Costs (as defined in the Letter Agreement) incurred by UHN for the UHN Planned Trial. 
  

	 	2.2.2	If Avro elects to proceed on its own with a Phase 1 Clinical Trial with respect to the first Licensed Product (“Avro Clinical Trial”), Avro will consult with the Dr. Jeffrey Medin,
and at his request, Dr. Medin will be included as an author on resulting publication(s), and subject to restrictions on publications as outlined in Section 2.2.4. For clarity, the obligation in the preceding sentence applies only to the
first Phase 1 Clinical Study of the first Licensed Product conducted by Avro and is limited to Dr. Jeffrey Medin. 

  

	 	2.2.3	UHN agrees to keep Avro informed of any clinical research or development conducted (or contemplated to be conducted) by or on behalf of UHN with respect to the UHN Planned Trial involving the Licensed Technology
as soon as reasonably practicable to ensure that UHN does not diminish or conflict with any licenses, options or other rights in Licensed Technology or Licensed Products granted to Avro, and to enable Avro and its Affiliates and Sublicensees to
comply with their regulatory obligations. For certainty and clarity, clinical research or development conducted (or contemplated to be conducted) by or on behalf of UHN includes clinical research or development conducted pursuant to the rights
retained under Section 2.2.1. 

  

	 	2.2.4	The UHN Principal Investigator, on behalf of UHN, retains the right to publish the final results of the UHN Planned Trial in a peer-reviewed journal or publication prior to any publication of the final results of
the Avro Clinical Trial in a peer-review journal or publication; provided that such right of publication priority in favor of the UHN Principal Investigator, on behalf of UHN, shall expire upon the earlier of (a) the termination or
discontinuation of the UHN Planned Trial for any reason, or (b) [***] after the last dose for the last patient has been administered for the Avro Clinical Trial. 


  
 *** Confidential Treatment
Requested *** 
  
 13 









	 	2.2.5	Avro acknowledges and agrees that (a) its rights to the Licensed Technology further to the License are restricted in accordance with the terms and provisions of this Agreement, and (b) subject to the
terms and conditions of Section 3.2 and this Section 2.2, UHN retains all rights to use, develop and commercially exploit the Licensed Technology outside the scope of the License. 


 

	2.3	Sublicenses. Avro and any of its Affiliates shall have the right to grant sublicense(s) through multiple tiers to the licenses and rights granted to it under this Agreement to any Sublicensee (the
“Sublicense(s)”); provided, however, that: 

  

	 	2.3.1	the Sublicense shall not have any terms which are inconsistent with this Agreement, including for clarity publication rights under Section 2.2.4; 


 

	 	2.3.2	Sublicensee(s) shall be required to make records available to UHN in accordance with the obligations outlined in Sections 4.11 and 4.12; and 


 

	 	2.3.3	unless otherwise indemnified by Avro or its Affiliate directly, the Sublicense shall provide that the Sublicensee will directly indemnify UHN on terms at least as favourable as those in Article 12 unless approved
otherwise in writing by UHN. 

 Upon termination of this Agreement for any reason, provided that a Sublicensee is not in
material breach of its Sublicense, UHN shall grant to such Sublicensee license rights and terms equivalent to the sublicense rights and terms which Avro previously granted to such Sublicensee. 

 

	2.4	Know-How Transfer and Right of Reference. 

  

	 	2.4.1	UHN shall, at Avro’s sole cost and expense, provide Avro with access to all of the Exclusively Licensed Know-How and
Non-Exclusively Licensed Know-How as same arises, and as soon as reasonably practicable after the Effective Date with respect to any then-existing Exclusively Licensed Know-How and Non-Exclusively Licensed Know-How in UHN’s and/or UHN’s CRO’s possession or control, in conjunction with
the exercise by the Avro of its rights under the License. The Parties will (a) work collaboratively together to facilitate the process for transferring the Exclusively Licensed Know-How and Non-Exclusively Licensed Know-How and (b) use reasonable best efforts to meet the proposed timelines as set out in Schedule “A” and any amendment to the
timelines shall be agreed to as between the Parties, each acting reasonably. The Parties will use reasonable best efforts to transfer all other Exclusively Licensed Know-How and
Non-Exclusively Licensed Know-How in accordance with this Section 2.4 or as otherwise reasonably agreed by the Parties. Details regarding transfer of Exclusively
Licensed Know-How and Non-Exclusively Licensed Know-How in the possession of the Fabry Trial Team shall be governed by Fabry
Trial Team Agreements. For the avoidance of doubt, the licenses with respect to the Exclusively Licensed Know-How and Non-Exclusively Licensed Know-How in the possession of the Fabry Trial Team shall be governed by this Agreement (including Section 2.1). 

  

	 	2.4.2	 Subject to UHN’s retention of rights further to Section 2.2, UHN hereby grants Avro an exclusive
right of reference in the Field of Use to any CTAs and other Regulatory Filings owned or controlled by UHN as of the Effective Date or during 



  
 *** Confidential Treatment
Requested *** 
  
 14 









	 	
the Term for Licensed Products to enable Avro to obtain Regulatory Approval of Licensed Products in the Territory or otherwise for any purpose in conjunction with the exercise by Avro of the
License and its rights under this Agreement. Upon Avro’s written request, UHN shall deliver to any Regulatory Authority an original letter authorizing Avro to reference and incorporate any such CTAs or other Regulatory Filings owned or
controlled by UHN; provided that, such letter shall be reasonably acceptable to Avro and shall be signed by the appropriate representative of UHN so that it is received by the applicable Regulatory Authority as soon as reasonably practicable (but in
no event later than [***] after Avro’s written request). UHN shall provide Avro with a copy of such letter as transmitted to such Regulatory Authority no later than [***] after such transmission and provide to Avro proof of delivery of such
letter. In the case of Indiana University acting as a contract manufacturer on behalf of UHN, to the extent UHN has such rights as set forth in its agreements with Indiana University, UHN hereby grants to Avro an exclusive right of reference to the
DMF of Indiana University for Licensed Products to enable Avro to obtain Regulatory Approval of Licensed Products in the Territory or otherwise for any purpose in conjunction with the exercise by Avro of the License and its rights under this
Agreement (taking into account that the DMF may contain confidential information of Indiana University that may not be shared with Avro). 

  

	 	2.4.3	UHN shall, at Avro’s sole cost and expense, provide Avro with access to copies of all Regulatory Filings created for, submitted to or received from an applicable Regulatory Authority relating to the Licensed
Products and all data contained therein, and any amendments, supplements, correspondence or further submissions (including adverse events and product complaints) to any of the foregoing, as well as the contents of any minutes from meetings (whether
in person or by audio conference or videoconference) with Regulatory Authorities, in each case relating to the Licensed Products. 

  

	 	2.4.4	For each patient in the UHN Planned Trial who goes off-study after having been subject to treatment, UHN shall provide to Avro, at Avro’s sole cost and expense, all
Patient Data relating to said patient as soon as reasonably practicable after such information becomes available to UHN and/or UHN CRO after the date upon which such patient goes off-study, including all
related Patient Data and the reason such patient went off-study. Details regarding transfer of off study Patient Data from the Fabry Trial Team to UHN and/or UHN CRO shall be governed by the Fabry Trial Team
Agreements. 

  

	 	2.4.5	 For each patient in the UHN Planned Trial, UHN and/or UHN CRO shall provide to Avro, at Avro’s sole
cost and expense, all Patient Data relating to said patient as soon as reasonably practicable upon such Patient Data becoming available to UHN and/or UHN CRO. Similarly, with respect to Sample Processing Data, provision of Reviewed Sample Processing
Data by UHN and/or UHN CRO to Avro within [***] of data becoming Reviewed Sample Processing Data shall be considered as soon as reasonably practicable. In the event that any adverse event is determined to be a serious and unexpected adverse reaction
event relating to the treatment (“SUSAR”) in accordance with the process as outlined in the Clinical Trial Protocol, UHN shall provide such information to Avro within [***] of the decision to report such SUSAR to the relevant regulatory
authority (or such other time period as the Parties may agree). Promptly following the disclosure of 



  
 *** Confidential Treatment
Requested *** 
  
 15 









	 	
a SUSAR to Avro, at Avro’s request, the UNH CRO shall provide all Patient Data with respect to such SUSAR and other information that is reasonably requested by Avro to Avro or its
designee(s), in each case for patient care purposes or to enable Avro or its Affiliates or Sublicensees to comply with any applicable laws, rules or regulations, and the UHN CRO shall discuss and answer all reasonable questions from Avro or its
designee(s) relating thereto. Details regarding transfer of Clinical Trial Data, Sample Processing Data, and SUSAR data from the Fabry Trial Team to UHN shall be governed by the Fabry Trial Team Agreements. Similarly, to the extent Avro or an
Affiliate or Sublicensee is conducting a clinical trial (including a Phase I Clinical Trial or a Pivotal Trial) relating to Fabry disease with the same vector in accordance with the Clinical Trial Protocol while the UHN Planned Trial is ongoing, and
in the event that any adverse event is determined to be a SUSAR in accordance with the process as outlined in the Clinical Trial Protocol, Avro shall provide such information to UHN within [***] of the decision to report such SUSAR to the relevant
regulatory authority (or such other time period as the Parties may agree). Promptly following the disclosure of a SUSAR to UHN, at UHN’s request, Avro shall provide all patient data with respect to such SUSAR and other information that is
reasonably requested by UHN to UHN, in each case for patient care purposes or to enable UHN to comply with any applicable laws, rules or regulations, and Avro shall discuss and answer all reasonable questions from UHN relating thereto.


  

	 	2.4.6	At Avro’s request, UHN and/or UHN CRO and Avro shall work jointly with an external contractor, at Avro’s sole cost and expense, to prepare monthly reports to provide to Avro for Clinical Trial Data
(“Monthly Clinical Trial Report”). UHN and/or UHN CRO shall provide such Monthly Clinical Trial Report to Avro within [***] after the end of each calendar month. The Parties shall work together to ensure such Monthly Clinical Trial
Report is in a form acceptable to Avro. Subject to the approval of the requisite Research Ethics Board, UHN shall ensure that all informed consent form(s) under which any Patient Data will be obtained permit (a) UHN to provide such Patient Data
to Avro and its Affiliates and Sublicensees, and (b) Avro and its Affiliates and Sublicensees to use such Patient Data in accordance with the terms of this Agreement. 


 

	 	2.4.7	 In accordance with applicable laws and in a manner consistent with good clinical practice, UHN shall
maintain, and shall cause its investigators and collaborating institutions (including the Fabry Trial Team) to maintain, complete and accurate records relating to the CTA, Regulatory Filings and the Patient Data to be provided to Avro. UHN, its
investigators and collaborating institutions (including the Fabry Trial Team), as applicable, shall retain such records relating to CTA and Regulatory Filings for a period of at least [***] after the date of delivery of such information or reports
to Avro (the “Data Retention Period”). During the Data Retention Period, Avro shall have the right, at its sole expense, during normal business hours, to provide a qualified person (“Auditor”) to inspect such
records of UHN, and its investigators and collaborating institutions (including the Fabry Trial Team), as applicable, for the purposes of verifying the accuracy of any information or reports delivered to Avro hereunder and UHN’s compliance with
the terms hereof; provided that, Avro shall give UHN and/or its investigators and collaborating institutions (including the Fabry Trial Team), as applicable, reasonable prior written notice (which shall be at least [***]) prior to Auditor conducting
any such audit. UHN may require Avro to enter into an additional, 



  
 *** Confidential Treatment
Requested *** 
  
 16 









	 	
customary nondisclosure agreement(s) prior to undertaking any such inspection as required by law or UHN policy or collaborating institution policy (as applicable). Any and all books, records,
reports and other documents of UHN that are inspected by Auditor pursuant to this Section 2.4.7 shall be deemed UHN Confidential Information. The Parties will comply with all applicable federal, state and provincial privacy legislation
including (as applicable) the Personal Information Protection and Electronic Documents Act, S.C. 2000, c. 5 (“PIPEDA”) and the Personal Health Information Protection Act, 2004, S.O. 2004, c. 3 (“PHIPA”). In
the conduct of such audits, Auditor may be given access to personal information in order to validate case report forms through source documentation. Auditor shall not copy documents containing personal information or take notes of personal
information. In the event that personal information about a UHN Planned Trial (or other clinical trial) subject is transferred to Avro and its employees or agents, Avro and its employees and agents shall only use the information for purposes
authorized in writing by UHN or required by law; and shall appropriately protect the information against loss, theft, unauthorized access, copying, or modification; not publish the information in a form that could reasonably permit identification of
the individual; not contact or attempt to contact the individual; and notify UHN and/or others as may be directed, immediately in writing upon becoming aware of any breach of this Section 2.4. Avro shall ensure that their employees and agents
comply with the terms and conditions of this Section 2.4. 

 The report from the audit shall be deemed Avro Confidential
Information. Avro may exercise the rights under this Section 2.4.7 only once during any Calendar Year. During the Data Retention Period, UHN shall, to the extent practicable, cause its investigators and collaborating institutions to comply with
the terms of this Section 2.4.7. If such audit reveals that UHN or its investigators or collaborating institutions, as applicable, failed to provide information or data that should have been provided to Avro hereunder, or that any element of
the information or reports delivered to Avro hereunder were incomplete or inaccurate, UHN promptly shall provide such missing information or data to Avro and/or complete and correct such information or reports and provide corrected information or
reports to Avro. 
  

	 	2.4.8	UHN and Avro will use reasonable best efforts to execute the Fabry Trial Team Agreements in a form mutually agreed by UHN and Avro within [***] after the Effective Date. Each Party acknowledges that delays by one
or more Fabry Trial Team Institution(s) is outside of the control of each of the Parties. The Parties further acknowledge that after using reasonable best efforts to present a draft Fabry Trial Team Agreement to the Fabry Trial Team Institution(s),
the Parties can only act reasonably in considering any revisions requested by the Fabry Trial Team Institution(s). 

  

	 	2.4.9	UHN will ensure clinical trial site agreements with any investigator or collaborating institution (including the Fabry Trial Team) relating to the UHN Planned Trial are consistent with UHN’s obligations,
and, subject to the terms of any executed Fabry Trial Team Agreement(s), will not diminish or conflict with any licenses, options or other rights in Licensed Technology or Licensed Products granted to Avro, under this Article 2, including the
License granted under Section 2.1 and the obligations outlined in this Section 2.4. 


  
 *** Confidential Treatment
Requested *** 
  
 17 









	 	2.4.10	Notwithstanding anything herein to the contrary, all costs or expenses to be incurred by Avro, and the design and content of the related deliverables to be delivered to Avro, pursuant to this Section 2.4
must be pre-approved by Avro in writing, and will be paid pursuant to Section 4.4. For clarity, the costs or expenses to be incurred by Avro pursuant to this Section 2.4 shall be limited to
reasonable, documented costs and expenses incurred by third parties only. 

 ARTICLE 3 - SRA IP & FURTHER
OPTIONS 
  

	3.1	SRA & Related Intellectual Property. The Parties contemplate the execution of one or more Sponsored Research Agreement(s). Each SRA will include and incorporate appropriate provisions in
respect of Avro rights and entitlements to SRA IP, including any agreement of the Parties to incorporate any such SRA IP (in whole or in part) into this Agreement as Licensed SRA IP. In such an event, the Parties shall execute all appropriate
documentation to record such inclusion as Licensed SRA IP and shall further update Schedule “D” as required. 

  

	3.2	Option Related to Improvements and Improved Therapies 

  

	 	3.2.1	Improvements Option. During the Option Term, and subject to any Third Party rights of (i) University of Wisconsin that exist as of the Effective Date or that may arise during the Option Term,
or (ii) that may arise as a result of UHN’s exercise of its retained rights pursuant to Section 2.2.1, UHN hereby grants to Avro and its Affiliates an exclusive option to obtain an exclusive license under any or all of UHN’s
interests in the Improvement Patents to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Products in
the Field of Use for the Territory (the “Option”). From time to time during the Option Term, or upon Avro’s written request during the Option Term, UHN shall (a) promptly inform Avro of the preparation or filing of any
Improvements Patents, (b) provide to Avro a summary of all Improvements created, conceived, developed or reduced to practice during the Option Term that are incorporated into said Improvements Patents, and (c) afford Avro a reasonable
opportunity during business hours to speak with UHN personnel (including the Principal Investigator) regarding the Improvements Patents in order to permit Avro to determine whether to exercise the Option. Within [***] of Avro’s receipt of
information from UHN regarding an Improvement Patent(s), Avro may (in its sole discretion) provide Notice to UHN of its intention to exercise the Option with respect to such Improvements Patent(s), such that such Improvements Patents become Optioned
Improvements Patents. On UHN’s receipt of such Notice, the Parties shall promptly (and in any event prior to the expiration of the Option Term) execute an amendment to this Agreement to include such Improvements Patents as Optioned Improvements
Patents on the existing terms and conditions set forth in this Agreement (which includes, without limitation, the reimbursement of UHN patent costs and expenses). For clarity, Avro will have the right to exercise the Option from time to time during
the Option Term as and when notified of such Improvements Patents in accordance with the terms of this Section 3.2.1. If UHN does not receive a Notice during the time period specified above from Avro of its intent to exercise the Option with
respect to such disclosed Improvement Patents, the option with respect to such disclosed Improvement Patents shall lapse, and the license to any Improvements Know-How associated with such Improvement Patents, shall terminate and UHN will be free to
dispose of the disclosed Improvement Patents in its sole and absolute discretion without any further notice or accounting to Avro. 


  
 *** Confidential Treatment
Requested *** 
  
 18 









	 	3.2.2	Improved Therapies Option. During the Option Term, UHN hereby also grants to Avro and its Affiliates an exclusive option to negotiate any or all of the following licenses and rights (the “Improved
Therapies Option”): 

 (a) subject to any Third Party rights of (i) University of Wisconsin that exist as of the
Effective Date or that may arise during the Option Term or (ii) that may arise as a result of UHN’s exercise of its retained rights pursuant to Section 2.2.1, an exclusive license under UHN’s interest in any or all of the
Improved Therapies Patents to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported products or services in the
Field of Use for the Territory, to the extent such rights are available in law; 
 (b) subject to any Third Party rights (i) of
University of Wisconsin that exist as of the Effective Date or that may arise during the Option Term or (ii) that may otherwise arise as a result of UHN’s exercise of its retained rights pursuant to Section 2.2, a non-exclusive license under UHN’s interest in any or all of the Improved Therapies Know-How to research, have researched, develop, have developed, make, have made, use,
have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported products or services in the Field of Use for the Territory, to the extent such rights are available in law; 

From time to time during the Option Term, or upon Avro’s written request during the Option Term, UHN shall (A) promptly inform Avro
of the preparation or filing of any Improved Therapies Patents, (B) provide to Avro a summary of all Improvements created, conceived, developed or reduced to practice prior to the Effective Date or during the Option Term that are incorporated
into said Improved Therapies Patents and (C) afford Avro a reasonable opportunity during business hours to speak with UHN personnel (including the Principal Investigator) regarding the Improved Therapies Patents and Improved Therapies Know-How in order to permit Avro to determine whether to exercise the Improved Therapies Option. Within [***] of receipt of information from UHN informing Avro of said Improved Therapies Patent(s), Avro may (in its
sole discretion) provide Notice to UHN of its intention to exercise any or all of Improved Therapies Option regarding said Improved Therapies Patent(s). On UHN’s receipt of such Notice, the Parties shall negotiate in good faith to enter into a
license agreement on terms and conditions to be agreed to by the Parties, including financial terms at least as favourable to UHN as those of this Agreement (which includes, without limitation, the reimbursement of UHN patent costs and expenses).
For clarity, Avro will have the right to exercise the Improved Therapies Option within [***] of such disclosure to Avro when any Improved Therapies are disclosed by UHN to Avro in accordance with the terms herein. 

  
 *** Confidential Treatment
Requested *** 
  
 19 









	 	3.2.3	Residual Rights. In the event that: 

 (a) UHN does not receive the
aforementioned Notice from Avro in respect of the Improved Therapies Option during the Option Term, or 
 (b) the Parties do not execute a
license with respect to the Improved Therapies Option, or 
 (c) the Parties do enter into a license with respect to the Improved Therapies
Option, but such license is terminated and the rights to exploit the Improved Therapies Patents is subsequently returned to UHN, 
 UHN will
then have the right to license the Improved Therapies Patents for the purpose of research, development and commercialization of any products or services thereunder in the Field of Use in its sole discretion and without any further notice or
accounting to Avro. 
 ARTICLE 4 - CONSIDERATION 
  

	4.1	Payment. Payments of funds to UHN shall be made to “University Health Network” and sent to the following address: 


University Health Network 

Technology Development & Commercialization 

College Street - Suite 150 

Heritage Building - MaRS Centre 

Toronto, Ontario, Canada, M5G 1L7 

Attention: tdc@uhnresearch.ca 
  

	4.2	License Maintenance/Upfront Fee. Upon execution of this Agreement, and on each anniversary of the Effective Date during the Term, Avro shall pay UHN (a) a
non-refundable and non-creditable (towards any other consideration owing pursuant to this Agreement with the exception of Section 4.6) license fee payment of [***]
until the first sale of a Licensed Product in [***], and (b) a non-refundable, non-creditable, one-time upfront fee of
seventy five thousand Canadian dollars (C$75,000) upon the execution of this Agreement. UHN will maintain [***] of these funds in a separate UHN account, to be maintained in support of UHN’s obligations pursuant to the accompanying letter
agreement to be executed concurrently with this Agreement (the “Letter Agreement”). 

  

	4.3	Reimbursement of Past Patent Costs. Avro shall reimburse UHN for all previously unreimbursed patent expenses incurred prior to and up to the Effective Date in respect of the filing, maintenance and prosecution of
the Fabry Patents (the “Patent Expenses”). For information purposes only, such costs are estimated to be [***]. All past patent costs are due and payable upon execution of this Agreement. 


 

	4.4	Reimbursement of Addition Costs and Expenses. For any third party out-of-pocket costs and expenses that are pre-approved by Avro in writing in accordance with Section 2.4.10, within [***] after [***], the incurring party will invoice Avro for any amounts owed by Avro under Section 2.4 that are not otherwise
accounted for in this Section 4. Avro will pay any undisputed amounts within [***] of receipt of the invoice, and any disputed amounts owed by a Party will be paid within [***] of resolution of the dispute. 


  
 *** Confidential Treatment
Requested *** 
  
 20 









	4.5	Royalties. 

  

	 	4.5.1	[***]. During the Royalty Term, Avro shall, on a country-by-country and Licensed Product-by-Licensed Product basis, pay to UHN a running royalty in the amount of (a) (i) [***] percent ([***]%) of Net Revenues for annual sales of such Licensed Product up to [***], (ii) [***]
percent ([***]%) of Net Revenues for annual sales of such Licensed Product between [***] up to [***], (iii) [***] percent ([***]%) of Net Revenues for annual sales of such Licensed Product between [***] up to [***], and (iv)
[***] percent ([***]%) of Net Revenues for annual sales of such Licensed Product in excess of [***], during the period in which (A) such sale would but for the licenses granted herein infringe any Valid Claims contained in the
Licensed Technology in such country, or (B) [***]. 

  

	 	4.5.2	[***]. During the Royalty Term, Avro shall, on a country-by-country basis and Licensed
Product-by-Licensed Product basis, in respect of countries in which [***], pay UHN a running royalty in the amount of [***] percent ([***]%) of Net
Revenues for such Licensed Product sold in [***]. 

 Amounts paid pursuant to this Section 4.5 shall be referred to as
“Royalties”. 
 Upon expiration of the Royalty Term with respect to a Licensed Product in a country, the license grant shall
become fully paid-up, royalty-free, perpetual and irrevocable for such Licensed Product in such country. 

To the extent that Avro or any of its Affiliates or Sublicenses obtains licenses to third party patent rights or other intellectual property in
order to practice the Patent Rights in Licensed Technology or to research, develop, manufacture or commercialize any Licensed Products and the aggregate royalty burden payable on a Licensed Product is greater than [***] percent ([***]%) (i.e., [***]
percent ([***]%) of the total Net Revenues of Licensed Product payable to UHN and any other Third Party), Avro and its Affiliates or Sublicensees may deduct from any royalty due to UHN hereunder [***] percent ([***]%) of the then applicable
aggregate royalty burden over said [***] percent ([***]%) (the “Deductible Third Party Royalties”) up to maximum reduction of [***] percent ([***]%) of the running Royalties owed UHN in any Quarterly Period hereunder (the
“Maximum Royalty Reduction”), with any Deductible Third Party Royalties that exceed the Maximum Royalty Reduction in any Quarterly Period carried over into immediately succeeding Quarterly Period(s) until exhausted, however
in no event shall the UHN Royalties owed in any such succeeding Quarterly Period(s) be reduced by greater than the Maximum Royalty Reduction. 

If the manufacture, use or sale of any Licensed Product or is covered by more than one of patent rights within the Licensed Technology,
multiple royalties shall not be due. 
  

	4.6	Sublicensing Fee. 

 In further partial consideration of the License, Avro shall pay to
UHN [***] percent ([***]%) of all Sublicensing Revenue (the “Sublicensing Fee”). Any amounts paid to UHN further to Section 4.2 (License Maintenance/Upfront Fee) and Article 5 (Milestones) shall be creditable by
Avro against amounts due to UHN further to this Section 4.6; however, the payments further to Section 4.2 and Article 5 shall not act as a cap on the payments owed further to this Section 4.6. 

  
 *** Confidential Treatment
Requested *** 
  
 21 








 To the extent that patent rights, other intellectual property rights or other rights or
obligations other than Licensed Technology are licensed, sublicensed or granted by Avro in addition to the Licensed Technology for which the Sublicensing Revenue is attributable, that portion of the consideration received by Avro and subject to this
Section 4.6 shall be equitably apportioned between the Licensed Technology and those other rights and obligations, and such apportionment shall be reasonable and in accordance with customary standards in the industry. Avro shall promptly
deliver to UHN a written report setting forth such apportionment. In the event UHN disagrees with the determination made by Avro, UHN shall so notify Avro within [***] of receipt of Avro’s report and the Parties shall meet to discuss and
resolve such disagreement in good faith. If the Parties are unable to agree in good faith as to such fair market values within [***] then (a) the matter shall be submitted in accordance with the dispute resolution process set forth in Article
14, and (b) UHN shall not be entitled to terminate this Agreement until a final determination has been made pursuant to Section 14.3. 
  

	4.7	Royalty Payments. The Royalties described in Section 4.5 shall accrue as of the date of receipt of Gross Revenue (either by Avro, its Affiliate or Sublicensee, as appropriate) and the Sublicensing Fee
described in Section 4.6 shall accrue as of the date of receipt of Sublicensing Revenues by Avro, and all amounts owing pursuant to Sections 4.5 and 4.6 shall be paid by Avro within [***] after the end of each Quarterly Period in which said
revenue/fee accrues. 

  

	4.8	Interest. All undisputed monies payable to UHN and not paid when due bear interest at the prime rate of interest quoted by the Bank of Canada, plus [***] percent ([***]%) per annum until the date paid to UHN. UHN
will be entitled to that interest in addition to any other rights or remedies available to it in respect of any payment default. 

  

	4.9	Withholdings. In the event that Avro is required by any law to withhold and/or make payments to tax authorities in respect of any payments payable by Avro to UHN under this Agreement, the liability of Avro under
this Agreement shall be to that extent satisfied, and such amounts shall be deemed to have been paid to UHN on their due dates, provided that Avro shall provide UHN with acceptable evidence of such payments. 


 

	4.10	Royalty Report. After the First Commercial Sale of a Licensed Product, Avro shall prepare a report (the “Royalty Report”) at the end of each Quarterly Period, setting out the Gross
Revenue, the Net Revenue (including an itemized statement of any permitted discounts, refunds and taxes deducted), the Sublicensing Revenue, and the number of Licensed Products sold, along with calculations of any Royalties and Sublicensing Fee that
are payable to UHN. Royalty Reports shall be due within [***] of the end of the relevant Quarterly Period. If no payments are due for any Quarterly Period, then the Royalty Report shall so state. 


 

	4.11	Complete Records. Avro shall keep true and accurate records and books of account (in accordance with generally accepted accounting principles) containing all data reasonably required for the computing and
verification of Gross Revenues, Net Revenues, Sublicensing Revenues and Royalties and Sublicensing Fee. Avro shall contractually require all Avro Affiliates and Sublicensees to keep same and provide a copy of same to Avro for purposes of inspection
pursuant to Section 4.12. Such records shall be maintained and accessible to UHN for at least [***] from the date of the payment to which such records are relevant. 


  
 *** Confidential Treatment
Requested *** 
  
 22 









	4.12	Inspection of Records. The records specified in this Agreement shall be available for inspection by UHN or their duly appointed auditor, but not more than once per Calendar Year, upon reasonable written notice
and during normal business hours at the principal place of business of Avro, for the sole purpose of verifying payments owed under this Agreement. The costs of any such inspection shall be borne by UHN unless the report of an auditor shows that the
Royalty Report was understated by more than [***] percent ([***]%) in respect of the period under review, in which case UHN’s reasonable out of pocket costs of the examination shall be paid by Avro. Avro may require such auditor to enter into a
commercially reasonable confidentiality agreement with Avro prior to being provided with any such records. 

  

	4.13	Discrepancy in Records. In the event that the records inspection conducted under Section 4.12 reveals any underpayment of royalties due to UHN, Avro will promptly pay UHN the full amount of that underpayment
together with interest thereon at the rate of interest referred to in Section 4.8. In the event that the records inspection conducted under Section 4.12 reveals any overpayment of royalties by Avro, the overpaid amount will be credited
against future amounts payable to UHN. 

  

	4.14	Confidentiality. The reports and records provided by Avro and its Affiliates and Sublicensees hereunder further to Sections 4.10, 4.11 and 4.12 shall be regarded as Avro’s (or its Affiliates’ or
Sublicensees’, as applicable) Confidential Information and UHN hereby covenants that it shall not use or disclose any information included in such reports for any purpose other than determining whether Avro, its Affiliates and Sublicensees have
complied with their obligations under this Agreement. UHN further agrees that, until such time as such information is no longer confidential through no fault of UHN, it shall maintain such reports and any information included therein in strict
confidence and treat such information in a manner at least as restrictive as its manner of treating its own Confidential Information of similar nature and in any event not less than with a reasonable degree of care. In addition, any summary of the
audit report and analysis, and the Royalty Payments amounts received by UHN (both in total, and particularized on a country-by-country basis) shall be considered
Confidential Information of Avro for purposes of this Section 4.14. 

  

	4.15	Philanthropic Commitment. Avro will donate funds equivalent to [***] ([***]%) of the (a) Royalties payable to UHN under Section 4.5 and (b) regulatory milestone payments payable to
UHN under Section 5.8 to organizations for the benefit of the Canadian Fabry community; provided, that, in no event shall such donated amounts exceed five hundred thousand Canadian dollars (C$500,000) in any calendar year. UHN shall direct how
such funds will be donated, subject to its consultation with Avro. Upon request by UHN, Avro shall provide all documentation and engage in such actions as reasonably requested by UHN to document and/or memorialize and/or verify any such donation.


 ARTICLE 5 - MILESTONES 
  

	5.1	Performance Milestones to Maintain License. Avro, itself or through its Affiliates or Sublicensees, shall be responsible for achieving the following performance milestones in the time periods as noted, for
purposes of maintaining the License: 

  

	 	5.1.1	[***]; and 

  

	 	5.1.2	[***]. 


  
 *** Confidential Treatment
Requested *** 
  
 23 








 The Parties acknowledge and agree that the Phase 1 Clinical Trial in Section 5.1.1 above may
be conducted by UHN (including the UHN Planned Trial) or another university or academic institution for purposes of satisfying this performance milestone. 
  

	5.2	Extension of Performance Milestone. The Parties may agree to extend: (a) the timelines for the performance of the Section 5.1 milestones, or (b) the Negotiation Period (as defined below in
Section 5.3). Any such agreement to extend such timelines shall be in writing. 

  

	5.3	Failure to Fulfill Performance Milestone(s). In the event that Avro is unable to satisfy one or more of the Section 5.1 milestone(s) within the timeline(s) as noted (or within the timeline(s) as
extended pursuant to Section 5.2 or Section 5.4) on the following basis: (a) for reasons beyond Avro’s reasonable control (including reasons relating to regulatory requirements or events or UHN’s failure to [***]), and
(b) despite Avro having used, and continuing to use (during any Negotiation Period as outlined herein) commercially reasonable efforts to develop at least one Licensed Product, then UHN and Avro shall negotiate in good faith for up to a period
of [***] (“Negotiation Period”) to reach agreement on revised timelines and/or revised milestones, during which Negotiation Period UHN shall not terminate this Agreement. Absent either of: (i) an extension, or revision
to the Section 5.1 milestones (such extension or revision not to be unreasonably withheld, conditioned or delayed), or (ii) Avro otherwise fulfilling the Section 5.1 milestone(s) within the Negotiation Period, UHN may terminate this
Agreement for material breach pursuant to Section 11.3.3 within its sole and absolute discretion. 

  

	5.4	Regulatory Authority Generated Delay. If Avro is unable to meet any milestone timeline as noted in Section 5.1.1 or Section 5.1.2 as a result of the relevant Regulatory Authority requesting additional
information or data or other Regulatory Authority delay, UHN and Avro shall negotiate in good faith, and acting reasonably, to agree upon the amount of time required to fulfill such request, and the relevant Section 5.1 milestone shall be
extended by such amount of time. 

  

	5.5	Licensed Product Development Milestone Payments. UHN shall be paid the following one-time milestone payments for a first Licensed Product to reach such milestone
(irrespective of indication and/or therapeutic area). Avro shall promptly provide Notice to UHN of the fulfillment of a milestone (whether fulfilled by Avro or its Affiliate or Sublicensee), and each noted milestone payment shall be due and payable
by Avro within [***] from the date that such milestone is met, subject to the payment deferral terms of Section 5.7: 

  

	 	5.5.1	[***]; and 

  

	 	5.5.2	[***]. 

  

	5.6	[Reserved]. 

  

	5.7	 Payment Deferral. In respect of reimbursable patent costs (pursuant to Section 4.3), and milestone
payments owed further to Section 5.5, (but only for such patent costs directly reimbursable by Avro and such milestones which have been achieved by Avro, and not by any acquirer or Sublicensee who achieves such milestone or is responsible for
any such patent cost reimbursement), payment shall remain due as indicated in the 



  
 *** Confidential Treatment
Requested *** 
  
 24 









	 	
aforementioned section(s), but the Parties agree that any amount due and payable that exceeds [***] percent ([***]%) of the total amounts (i.e. gross total) of any investment raise(s) and
financing(s) (e.g. any of seed financing, Series A Financing, Series B Financing or other series of financing) up to such date for which the relevant milestone and/or patent costs are due shall be deferred to the next investment raise/financing. As
such, any outstanding amounts shall become payable upon the next investment raise, again subject to [***] percent ([***]%) cap of the total amount (i.e. gross total) of such investment raise/financing until such time as all unpaid amounts are paid
in full. All unpaid amounts will collect interest as further set out in Section 4.8. All unpaid and deferred amounts owed pursuant to this Section 5.7 will become immediately payable upon the earlier to occur of: (a) closing of a
merger or acquisition of Avro, (b) sale of substantially all of Avro’s assets (including this Agreement) relating to the Licensed Products to a non-Affiliated Third Party during the term of this
Agreement, (c) Avro granting an exclusive sublicense under the Licensed Technology to a Third Party for purposes of commercializing Licensed Products, or (d) upon an initial public offering (IPO) of Avro shares. 


 

	5.8	Regulatory Approval Milestone Payments. UHN shall be paid the following milestone payments in respect of each Licensed Product(s). Avro shall promptly provide Notice to UHN of the fulfillment of a milestone
(whether such milestone is achieved by Avro or its Affiliate or Sublicensee). Each noted milestone payment is payable by Avro within [***] from the date that such milestone is met: 


 

	 	5.8.1	[***]; 

  

	 	5.8.2	[***]; and 

  

	 	5.8.3	[***]. 

  

	5.9	[Reserved]. 

 ARTICLE 6 - REPRESENTATIONS, WARRANTIES AND LIABILITY 

 

	6.1	UHN Reps & Warranties. UHN represents, warrants and covenants to Avro that: 

  

	 	6.1.1	it is duly incorporated and organized and validly existing under the laws of Ontario, and has all requisite corporate power and authority to enter into and perform its obligations under the Agreement;


  

	 	6.1.2	it has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and perform its obligations hereunder;


  

	 	6.1.3	the execution and delivery of this Agreement by UHN and the performance of its obligations under the Agreement shall not result in either a breach or violation of any of the provisions of, or constitute a default
under, or conflict with or cause the acceleration of, any obligation of UHN under: 

 (a) any agreement to which UHN is a
party or is otherwise bound by; 

  
 *** Confidential Treatment
Requested *** 
  
 25 








 (b) any judgment, decree, order or award of any court, governmental body or arbitrator having
jurisdiction over UHN; 
 (c) any license, permit, approval, consent or authorization held by UHN; or 

(d) any applicable law, statute, ordinance, regulation or rule; 
  

	 	6.1.4	as on the Effective Date, UHN is the sole owner of all right, title and interest in and to the Licensed Patents then listed in Schedules “C”; and 


 

	 	6.1.5	UHN will disclose all Improved Therapies that exist as of the Effective Date and of which UHN has knowledge, within [***] of the Effective Date. 


 

	6.2	Avro Reps & Warranties. Avro represents and warrants to UHN that: 

  

	 	6.2.1	it is duly incorporated and organized and validly existing under the laws of the State of Delaware and has all the requisite corporate power and authority to enter into and perform its obligations under the
Agreement; 

  

	 	6.2.2	it has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of the Agreement and the performance of its obligations hereunder
and to cause all necessary meetings of directors and shareholders of Avro to be held for such purposes; 

  

	 	6.2.3	the execution and delivery of this Agreement by Avro and the performance of its obligations hereunder shall not result in either a breach or violation of any of the provisions of, or constitute a default under,
or conflict with or cause the acceleration of, any obligation of Avro under: 

 (a) any agreement to which Avro is a party or
is otherwise bound by; 
 (b) any of the terms and provisions of the organizing documents or bylaws, or resolutions of the board of
directors (or any committee thereof), of Avro; 
 (c) any judgment, decree, order or award of any court, governmental body or arbitrator
having jurisdiction over Avro; 
 (d) any license, permit, approval, consent or authorization held by Avro; and 

(e) any applicable law, statute, ordinance, regulation or rule. 
  

	6.3	Limitations of Liability. EXCEPT AS OTHERWISE EXPRESSLY SET OUT IN THIS AGREEMENT: 

  

	 	6.3.1	EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF ANY KIND, INCLUDING WARRANTIES OF MERCHANTABILITY, SAFETY OR FITNESS FOR ANY PARTICULAR
PURPOSE OF THE LICENSED TECHNOLOGY, OR THAT THE LICENSED TECHNOLOGY CAN BE EXPLOITED TO GENERATE REVENUES; 


  
 *** Confidential Treatment
Requested *** 
  
 26 









	 	6.3.2	UHN DOES NOT WARRANT OR REPRESENT THAT ISSUED PATENTS ARE VALID, OR PENDING PATENT APPLICATIONS WILL ISSUE, OR WHEN ISSUED WILL BE VALID, OR THAT THE PRACTICE OR EXPLOITATION OF ANY LICENSED TECHNOLOGY PROVIDED
PURSUANT TO THIS AGREEMENT, DOES NOT, OR WILL NOT, CONSTITUTE INFRINGEMENT OF RIGHTS OF THIRD PARTIES; 

  

	 	6.3.3	NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGE OR LOSS OF BUSINESS OR LOSS OF PROFITS SUFFERED BY SUCH OTHER PARTY RESULTING FROM THE USE
OR OTHER EXPLOITATION OF THE LICENSED TECHNOLOGY, INCLUDING WITHOUT LIMITATION THE SALE OF ANY LICENSED PRODUCTS. FURTHERMORE, UHN MAKES NO REPRESENTATION THAT THE LICENSED TECHNOLOGY IS FREE FROM DEFECT OR LIABILITY OF INTELLECTUAL PROPERTY
INFRINGEMENT. 

 ARTICLE 7 - FURTHER COVENANTS AND OBLIGATIONS 

 

	7.1	Avro Covenants/Obligations. Avro covenants and agrees for the benefit of UHN that it shall: 

  

	 	7.1.1	use reasonable efforts to provide Notice to UHN in the event that the Principal Investigator becomes a shareholder of Avro; 

  

	 	7.1.2	not engage the Principal Investigator or other UHN employees for the conduct of research activities utilizing UHN resources and/or facilities absent a Sponsored Research Agreement or such other appropriate
agreement, or otherwise the written consent of UHN; provided, for clarity, that this Section 7.1.2 shall apply to the Principal Investigator in his appointment and scientific research at UHN only (and not with respect to
any other university, hospital, facility, institution or entity); 

  

	 	7.1.3	use commercially reasonable efforts to exercise the License granted herein and otherwise exploit the Licensed Technology in accordance with the terms of this Agreement, and with all applicable laws, statutes,
ordinances, regulations, guidelines and rules, including all applicable statutes and regulations and applicable guidelines set forth by the Canadian Institutes of Health Research (CIHR), National Institutes of Health (NIH) or other governmental
agencies where applicable; 

  

	 	7.1.4	ensure that all of its employees, representatives, agents, consultants, Sublicensee(s), Affiliate(s) and any other Third Parties having access to the subject matter of this Agreement are aware of any and all
confidentiality obligations, and are legally bound by similar obligations; 

  

	 	7.1.5	cause to be applied to Licensed Product(s) (as appropriate) any markings required by applicable government statutes and laws to maintain continued validity and enforcement of proprietary rights in Licensed
Technology (as applicable); 


  
 *** Confidential Treatment
Requested *** 
  
 27 









	 	7.1.6	ensure that the terms and conditions of any Sublicense are consistent with the terms and conditions of this Agreement; and 

  

	 	7.1.7	in addition to any diligence requirements or obligations of this Agreement, use commercially reasonable efforts to develop and commercialize one or more Licensed Products. 


 

	7.2	UHN Covenants. UHN covenants and agrees for the benefit of Avro that it shall: 

  

	 	7.2.1	ensure that all employees, staff members, students, and any other UHN agents or representatives having access to the subject matter of this Agreement are aware of any and all obligations under this Agreement,
including confidentiality obligations, and have agreed to be legally bound by them; 

  

	 	7.2.2	use reasonable best efforts to conduct and enroll and dose at least [***] patients in the UHN Planned Trial with a [***] follow-up phase; provided, however, that UHN shall
not be deemed to be in breach of the foregoing obligation in the event that UHN discontinues the UHN Planned Trial due to events outside of the reasonable control of UHN (i.e., actions taken by Regulatory Authorities, due to a material safety issue
of a Licensed Product, or due to Avro’s uncured breach of its payment obligations in the Letter Agreement); and 

  

	 	7.2.3	not grant any rights in the Licensed Technology to any Person that would conflict with the rights granted to Avro hereunder. 


ARTICLE 8 - MANAGEMENT OF INTELLECTUAL PROPERTY RIGHTS 
  

	8.1	Responsibility for Patent Rights. Avro will assume responsibility for the preparing, filing, prosecuting, maintaining and defending in all agency proceedings (e.g., reissues, reexaminations, oppositions and
interferences), using patent counsel reasonably acceptable to UHN, patent rights within the Licensed Technology to the extent such patent rights are relevant to the Field of Use, or Avro is otherwise deemed to be responsible for prosecution in
accordance with the terms of a Sponsored Research Agreement (“Field Patent Rights”) during the Term. Avro shall copy UHN on all patent prosecution documents and give UHN reasonable opportunities to advise Avro on such filing,
prosecution and maintenance. In the event Avro desires to abandon any patent or patent application within the Field Patent Rights, Avro shall provide UHN with reasonable prior written notice of such intended abandonment or decline of responsibility.
If UHN elects to continue such patent or patent application, the Parties shall consult and Avro may elect to retain responsibility therefor. Otherwise, the right to prepare, file, prosecute, maintain and defend the relevant Field Patent Rights, at
UHN’s expense, shall revert to UHN. In such event, such UHN paid-for rights shall be removed from the definition of Licensed Patents under this Agreement and the licenses granted to Avro and its
Affiliates as to such rights shall terminate. UHN retains its rights to prepare, file, prosecute, and maintain, and defend in all agency proceedings (e.g. reissues, reexaminations, oppositions and interferences), at UHN’s expense, patent rights
within the Licensed Technology that are relevant outside the Field of Use (“UHN Patent Rights”). To the extent that patent rights are relevant both inside and outside the Field of Use, during the Option Term the Parties shall work
cooperatively to make decisions with respect to preparing, filing, prosecuting, maintaining and defending such patent rights in all agency proceedings such that neither Party’s rights are jeopardized. 


  
 *** Confidential Treatment
Requested *** 
  
 28 









	8.2	Patent Extensions and Orange Book Listings. If elections with respect to obtaining patent term extensions (including, without limitation, any available pediatric extensions) or supplemental protection
certificates or their equivalents in any country with respect to Field Patent Rights are available, Avro shall have the sole and exclusive right to make any such elections based on Licensed Products. With respect to data exclusivity periods (such as
those periods listed in the FDA’s Orange Book (including, without limitation, any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or orphan exclusivity periods, and all
equivalents in any country), Avro shall have the sole and exclusive right to seek and maintain all such data exclusivity periods available for the Licensed Products. With respect to all of the rights and activities identified in this
Section 8.2, UHN hereby appoints Avro as its agent for such purposes with the authority to act on UHN’s behalf with respect to the Field Patent Rights in a manner consistent with this Agreement. 


 

	8.3	Notification of Infringement. Each Party agrees to provide written notice to the other Party promptly after becoming aware of any infringement of the Field Patent Rights or UHN Patent Rights by a Third Party and
of any available evidence thereof. 

  

	8.4	Right to Prosecute Infringements. 

  

	 	8.4.1	Avro Right to Prosecute. As between the Parties, Avro shall have the first and exclusive right, but not the obligation, under its own control and at its own expense, to prosecute any Third Party infringement of
the Field Patent Rights and/or UHN Patent Rights, subject to Sections 8.5 and 8.6. The total cost of any such infringement action commenced or defended solely by Avro shall be borne by Avro. 


 

	 	8.4.2	UHN Right to Prosecute. If within [***] after having been notified of any alleged infringement that is material and competitive in the marketplace Avro is unsuccessful in persuading the alleged infringer to
desist and shall not have brought and shall not be diligently prosecuting an infringement action, then UHN shall have the right, but shall not be obligated, under its own control and at its own expense, to prosecute any infringement of the Field
Patent Rights and/or UHN Patent Rights. 

  

	8.5	Declaratory Judgment Actions. If a declaratory judgment action is brought naming UHN or Avro or any of its Affiliates or Sublicensees as a defendant and alleging invalidity, unenforceability or non-infringement of any Field Patent Rights and/or UHN Patent Rights, Avro or UHN, as the case may be, shall promptly notify the other Party in writing. With regards to the Field Patent Rights, or to the extent
litigation of the UHN Patent Rights remain under UHN’s control, Avro may elect, upon written notice to UHN within [***] after receiving or giving notice of the commencement of such action, to take over the sole control of such action at its own
expense. If Avro does not defend any such action, then UHN shall have the right, but shall not be obligated, to defend such action at UHN’s expense. 

  

	8.6	 Recovery. In the event that either Party exercises the rights conferred in this Article 8 and recovers any
damages or other sums in such action, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in
connection therewith (including, without limitation, attorneys fees). If such recovery is insufficient to cover all such costs and expenses of both Parties, [***]. If after 



  
 *** Confidential Treatment
Requested *** 
  
 29 









	 	
such reimbursement any funds shall remain from such damages or other sums recovered, such funds shall be retained by the Party that controlled the action or proceeding under this Article 8;
provided, however, that (a) if Avro is the Party that controlled such action or proceeding, the remaining recovery received by Avro shall be shared [***] allocated to Avro, [***]) allocated to UHN, and (b) if UHN is the Party that
controlled such action or proceeding, the remaining recovery received by UHN shall be shared [***] allocated to UHN, [***] allocated to Avro. 

  

	8.7	Cooperation. Each Party agrees to cooperate in any action under this Article 8 which is controlled by the other Party, including, without limitation, joining such action as a party plaintiff if necessary or
desirable for initiation or continuation of such action; provided that the controlling Party reimburses the cooperating Party promptly for any reasonable costs and expenses incurred by the cooperating Party in connection with providing such
assistance. 

  

	8.8	Patent Certifications. UHN shall notify and provide Avro with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a Patent Right
pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) or any other similar patent certification by a third party, and any foreign equivalent thereof. Such
notification and copies shall be provided to Avro within [***] after UHN receives such certification. 

  

	8.9	Patent Challenges. UHN will have the right to terminate this Agreement in full upon [***] prior written notice to Avro in the event that Avro or any of its Affiliates or Sublicensees (to the extent related to
rights granted to a Sublicensee under this Agreement) institutes any claim in a legal or administrative proceeding challenging the validity of any Licensed Patents (except as a defense against a claim, action or proceeding asserted by UHN against
Avro or its Affiliates or Sublicensees) (a “Patent Challenge”); provided, with respect to any such Patent Challenge by any Sublicensee of Avro, UHN will not have the right to terminate this Agreement under this
Section 8.9 if Avro (a) causes such Patent Challenge to be terminated or dismissed or (b) if permitted in accordance with applicable Law, terminates such Sublicensee’s sublicense to the Licensed Patents being challenged by the
Sublicensee, in each case ((a) and (b)) within [***] of UHN’s notice to Avro under this Section 8.9. Notwithstanding the foregoing, UHN’s termination right under this Section 8.9 will not apply to any Affiliate of Avro that first
becomes an Affiliate of Avro after the Effective Date of this Agreement in connection with a License Transfer, where such Affiliate of Avro was undertaking activities in connection with a Patent Challenge prior to such License Transfer.


 ARTICLE 9 - CONFIDENTIAL INFORMATION 
  

	9.1	 Confidentiality. The Receiving Party shall take all reasonable measures, and at least the same measures as
it takes in respect of its own Confidential Information of a similar nature, to keep confidential the Confidential Information of the Disclosing Party. The Receiving Party may disclose such Confidential Information to those of its directors,
officers, employees, subcontractors, consultants and agents (collectively, “Representatives”) having a need to know such information in connection with exercising the Receiving Party’s rights and/or fulfilling the
Receiving Party’s obligations under this Agreement. With respect to Avro, Representatives also include Affiliates and proposed and actual Sublicensee(s). The Receiving Party will ensure that any of its Representatives having access to the
Confidential Information of the Disclosing Party 



  
 *** Confidential Treatment
Requested *** 
  
 30 









	 	
are under a legal obligation to maintain such Confidential Information in confidence and are duly informed of this obligation. The Receiving Party will neither use nor disclose to any other party
any of the Confidential Information of the Disclosing Party except as expressly permitted under this Agreement. The terms of this Agreement are the Confidential Information of both Parties. During the Term, information relating to Licensed
Product(s) in the Field of Use is the Confidential Information of Avro. The confidentiality provisions as outlined in this Article 9 shall survive expiration or earlier termination of this Agreement for a period of [***]. 


 

	9.2	Equitable Relief / Disputes. The Parties acknowledge that a breach of this Article 9 by either Party or any of its Representatives may cause irreparable harm and that, notwithstanding any other term or provision
of this Agreement, the non-breaching Party may be entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the
exclusive remedies but shall be in addition to all other remedies available at law or equity. 

  

	9.3	Disclosure to Advisors. Notwithstanding the confidentiality obligations of this Agreement, each Party shall be permitted to disclose the terms of this Agreement without the prior written consent of the other
Party to those of its [***]. 

  

	9.4	Other Permitted Disclosures. Notwithstanding the confidentiality obligations of this Agreement, the Receiving Party shall be permitted to disclose the Confidential Information of the Disclosing Party or any other
information associated with the Agreement, without the prior written consent of the Disclosing Party, (a) to the extent required to be disclosed by law (including access to information laws, securities laws, regulations and listing requirements
in Canada, United States and other jurisdictions) or an order of a court, tribunal, or government agency, provided that to the extent legally permissible the Receiving Party (i) gives to the Disclosing Party prompt written notice of the
required disclosure of any Confidential Information in order to allow the Disclosing Party reasonable opportunity to seek a confidentiality order or the like, and (ii) cooperates with efforts of the Disclosing Party (at the Disclosing
Party’s expense) in connection therewith; and (b) as required to be disclosed in connection with the filing with, or approval, certification or endorsement from, any governmental body or medical protocol, in each case for a Licensed
Product(s), provided that the information disclosed pursuant to this clause (b) is not the inventive subject matter of an unpublished patent application. 

  

	9.5	 Press Releases. Avro or its Affiliates may prepare and disclose via press release any Patient Data for the
UHN Planned Trial (a) after an academic publication, interim report, abstract or presentation of data/results from the UHN Planned Trial has been made or authorized by Dr. Jeff Medin or any other clinical trial site (“Interim
Disclosure”) (such publication or presentation subject to Sections 10.1 and 10.2) but restricted as follows: (i) the UHN Planned Trial data and results referred to or otherwise discussed in the press release shall be limited to
published data/results and (ii) the UHN Principal Investigator shall be granted a reasonable opportunity to review and comment on the accuracy of technical and scientific data and conclusions relating to same prior to publication of the press
release; or (b) as required by applicable laws, rules or regulations (including a press release corresponding to any securities disclosure, such as pursuant to a Form 8-K), including by the rules or
regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity. The intention of Dr. Jeff




  
 *** Confidential Treatment
Requested *** 
  
 31 









	 	
Medin as of the Effective Date is to publish or present interim data, in one or more forums, as is reasonable in light of the data generated during the UHN Planned Trial. For clarity, the
restrictions set forth in this paragraph apply only to the UHN Planned Trial. 

 Subject to Section 10.2.1, Avro or its
Affiliates may prepare and disclose via any press release, publication or presentation any data, results or reports relating to the Licensed Products (including with respect to the Licensed Technology) in Avro’s sole discretion without prior
review and/or approval by UHN or Dr. Jeff Medin, other than the Patient Data for the UHN Planned Trial which is addressed by the paragraph above. 

Other than as agreed to by the Parties, UHN shall only issue press releases with respect to the Licensed Technology in accordance with Sections
10.1 and 10.2.2. 
 ARTICLE 10 - PUBLICATION 
  

	10.1	Publications. Avro recognizes that, under UHN policies further to its obligations and responsibilities as an academic and teaching/research hospital affiliated with the University of Toronto, the results of
research conducted at UHN (including ongoing research of the Principal Investigator with respect to the Licensed Technology) and research conducted jointly with other institutions (the UHN Planned Trial) must be publishable, and as such agrees that
the Principal Investigator or the researchers employed by UHN who are engaged in any such research, as well as their collaborators, shall be permitted to present at symposia, national, or regional professional meetings, and to publish in journals,
theses or dissertations, or otherwise, the methods and results of such research. Avro shall be furnished a copy of any proposed (a) publication (including publication in conjunction with collaborators under the UHN Planned Trial) at least [***]
before submission of such proposed publication, and (b) public oral presentation/seminar at least [***] before delivery of such presentation/seminar. During that time, Avro shall have the right to (i) review the material for Confidential
Information provided by Avro and (ii) assess the patentability of any invention described in the material. If Avro decides that a patent application should be filed, the publication or presentation may, at Avro’s request, be delayed an
additional [***]. At Avro’s request, Confidential Information provided by Avro shall be deleted. Publications submitted by UHN to Avro pursuant to this Section 10.1 shall remain confidential, and may only be made the subject of a press
release by Avro or its Affiliates (A) after the date of the first publication or disclosure, or (B) as permitted pursuant to Section 9.5. 

  

	10.2	Use of Names / Additional Permitted Disclosures. 

  

	 	10.2.1	Avro and its Affiliates and Sublicensees shall not use the name of “University Health Network” or any variation, adaptation, or abbreviation thereof, or of any of its trustees, officers, faculty,
students, employees, clinical staff or agents, or any trademark owned by UHN, or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of UHN. The foregoing
notwithstanding, without the consent of UHN, Avro may indicate that it is licensed by UHN under the Licensed Technology and identify the inventors (including the Principal Investigator), their affiliation with UHN, and their relationship to Avro,
and further, Avro may comply with disclosure requirements of all applicable laws relating to its business, including, without limitation, United States and state securities laws. 


  
 *** Confidential Treatment
Requested *** 
  
 32 









	 	10.2.2	UHN shall not use the name of Avro or its Affiliates or Sublicensees or any variation, adaptation, or abbreviation thereof, or of any of their respective Representatives, or any trademark owned by Avro or its
Affiliates or Sublicensees, or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of Avro or its Affiliates or Sublicensees (as applicable). Notwithstanding any term
or provision of this Agreement (including any obligation of Confidentiality), without the consent of Avro, UHN may indicate that it has licensed the Licensed Technology to Avro and identify the inventors (including the Principal Investigator), his
affiliation with UHN, his relationship (if any) to Avro, and the achievement of clinical, regulatory or commercialization milestones hereunder and, to the extent required by applicable law, sums of monies received by UHN; and further, UHN may comply
with disclosure requirements of all applicable laws relating to its business, including, without limitation, Provincial and Federal access to information laws. 


ARTICLE 11 - TERM & TERMINATION 
  

	11.1	Term. Unless terminated pursuant to Sections 11.2, the term of this Agreement shall commence on the Effective Date and shall remain in effect until the expiration of the Royalty Term for all Licensed
Products, unless earlier terminated in accordance with the provisions of this Agreement or otherwise mutually agreed (the “Term”). 

  

	11.2	Voluntary Termination by Avro. Avro shall have the right to terminate this Agreement, for any reason, upon at least [***] prior written notice to UHN, such notice to state the date at least [***] in the future
upon which termination is to be effective. 

  

	11.3	Termination for Default. 

  

	 	11.3.1	Nonpayment and Insurance. In the event Avro fails to pay any undisputed amounts due and payable to UHN hereunder, and fails to make such payments within [***] after receiving written notice of such failure, or in
the event that Avro fails to have or maintain insurance as outlined in Section 13.6, UHN may terminate this Agreement upon written notice to Avro, subject to completion of the dispute resolution process set forth in Section 14.1 and
Section 14.2 and a final determination pursuant to mandatory arbitration under Section 14.3 and unless otherwise cured further to said process as outlined therein. 


 

	 	11.3.2	Material Breach by UHN. In the event UHN commits a material breach of its obligations under this Agreement, and fails to cure that breach within [***] after receiving written notice thereof, Avro may terminate
this Agreement immediately upon written notice to UHN, subject to completion of the dispute resolution process set forth in Section 14.1 and Section 14.2 unless otherwise cured further to said process as outlined therein.


  

	 	11.3.3	Material Breach by Avro. In the event Avro commits a material breach of its obligations under this Agreement, except for breach as described in Section 11.3.1, and fails to cure that breach within [***]
after receiving written notice thereof, UHN may terminate this Agreement immediately upon written notice to Avro, subject to completion of the dispute resolution process set forth in Section 14.1 and Section 14.2 unless otherwise cured further
to said process as outlined therein. 


  
 *** Confidential Treatment
Requested *** 
  
 33 









	 	11.3.4	Modification for Material Breach by UHN of Sections 2.1, 2.4, 6.1, 7.2.2, or 7.2.3 or Article 9. Notwithstanding any other provisions of this Agreement and in addition to the deductions otherwise permitted under
this Agreement, (a) if Avro has the right to terminate this Agreement under Sections 2.1, 2.4, 6.1, 7.2.2, or 7.2.3 or Article 9 as a result of an uncured breach which has a demonstrable material impact on Avro (including expiration of all
applicable cure periods thereunder and final determination pursuant to mandatory arbitration under Section 14.3), in lieu of exercising such termination right, Avro may elect by written notice to UHN before the end of such applicable cure
period to have this Agreement continue in full force and effect and instead have, starting immediately after the end of such applicable cure period, each of the following will be reduced by [***] percent ([***]%): any future milestone payments
payable under Sections 5.5 or 5.8, any Royalties under Section 4.5, any Sublicensing Revenue sharing under Section 4.6 and any License Transfer Fee attributable to this Agreement (but not the IL-12
Agreement) under Section 16.4.2. 

  

	 	11.3.5	Modification for Material Breach by UHN of Letter Agreement, Supply Agreement or Purchase Order(s). If UHN or the Principal Investigator breaches any obligations pursuant to the Letter Agreement,
Supply Agreement or Purchase Order(s), and said breach has a demonstrable material impact on Avro, and is not cured within [***] of notification of said breach, each of the following will be reduced by [***] percent ([***]%): any future milestone
payments payable under Sections 5.5 or 5.8, any Royalties under Section 4.5, any Sublicensing Revenue sharing under Section 4.6 and any License Transfer Fee attributable to this Agreement (but not the
IL-12 Agreement) under Section 16.4.2. 

  

	11.4	Bankruptcy. UHN may terminate this Agreement upon written notice to Avro if Avro becomes insolvent, is adjudged bankrupt, applies for judicial or extrajudicial settlement with its creditors, makes an assignment
for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy appointed by reason of its insolvency, or in the event an involuntary bankruptcy action is filed against Avro and not
dismissed within [***], or if Avro becomes the subject of liquidation or dissolution proceedings or otherwise discontinues business. 

  

	11.5	Disputed Termination Right. If the non-terminating Party disputes in good faith the right of the other Party to terminate this Agreement for any reason other than
Avro’s right to terminate for convenience pursuant to Section 11.2, and such non-terminating Party provides the terminating Party written notice of such dispute within [***] after the terminating
Party’s notice, as applicable, then the terminating Party will not have the right to terminate this Agreement unless and until the Parties have followed with the dispute resolution mechanism as outlined in Section 14.1 and
Section 14.2 and, as required, final determination pursuant to mandatory arbitration under Section 14.3, after which time the terminating Party has the right to terminate this Agreement in accordance with the terms and conditions set forth
herein. It is understood and agreed that (a) during the pendency of such dispute, all of the terms and conditions of this Agreement will remain in effect, and (b) the non-terminating Party will have
the right to cure such breach that is the subject matter of the dispute. 


  
 *** Confidential Treatment
Requested *** 
  
 34 









	11.6	Effects of Early Termination. In the event of the termination of this Agreement: 

  

	 	11.6.1	the License will be terminated, all rights to the Licensed Technology shall revert to UHN, and Avro shall cease and desist any further use or exploitation of, and otherwise cease to derive any benefit from, the
Licensed Technology, and within [***] either destroy or return to UHN, further to UHN’s instructions all of UHN’s property, including all Licensed Technology; 


 

	 	11.6.2	each Receiving Party shall return to the Disclosing Party or destroy (as directed by a Disclosing Party) all copies of said Disclosing Party’s Confidential Information in a manner consistent with any
applicable laws and regulations; 

  

	 	11.6.3	Avro shall within [***] of the date of such termination, pay UHN all current amounts then owed to UHN pursuant to this Agreement. For purposes of certainty and clarity, no term or provision of this Agreement
shall be construed to waive the payment of any monies to UHN accrued at the date of said termination, or arising thereafter; 

  

	 	11.6.4	the Parties shall take all necessary steps in a prudent business manner to wind-down any ongoing activities and to effect the orderly termination of this Agreement; and 


 

	 	11.6.5	Avro and its Affiliates and Sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as
of the effective date of termination, provided that (a) Avro pays UHN the applicable running royalty or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement, and (b) Avro and
its Affiliates and Sublicensees shall complete and sell all work-in-progress and inventory of Licensed Products within [***] after the effective date of termination.


 ARTICLE 12 - INDEMNIFICATION 
  

	12.1	Indemnification. Notwithstanding Section 6.3, Avro agrees to indemnify, save harmless, and defend UHN and its directors, officers, research staff, employees, clinical staff, research trainees, students, and
agents (collectively, “UHN Indemnitees”), against any and all Third Party claims, suits, losses, damages, costs, fees, and expenses (including reasonable legal expenses) (collectively, “Claims”),
arising out of (a) any liability claims with respect to any Licensed Product(s), (b) any Third Party intellectual property infringement or alleged infringement claims with respect to Licensed Product(s), and (c) any damages, losses, or
liabilities whatsoever with respect to death or injury to any person and damage to any property arising from this Agreement and the License, including, without limitation, the manufacture, design, distribution, and offer for sale of Licensed
Product(s) or otherwise arising from any exploitation of the Licensed Technology, except in each case to the extent caused by the negligence or willful misconduct of UHN Indemnitees or a breach of this Agreement by UHN. 


ARTICLE 13 - INSURANCE 
  

	13.1	 Avro Insurance. No later than [***] prior to the earlier of the (a) first use by Avro of Licensed
Technology in humans, or (b) first sale by Avro of Licensed Product(s), Avro (at its expense) shall obtain and maintain (as appropriate) general liability, product 



  
 *** Confidential Treatment
Requested *** 
  
 35 









	 	
liability and clinical trial liability insurance (the “Avro Insurance”) of a minimum of [***] per occurrence and [***] annual aggregate, naming UHN as an additional
insured. Avro shall provide to UHN a “Certificate of Insurance” evidencing compliance with this provision within [***] prior to such first use. Avro shall, at its own expense, obtain and maintain the Avro Insurance from the
initial date required by this Section 13.1 for the Term and for a period of [***] thereafter. In the alternative, Avro may self-insure subject to prior approval of UHN. 


 

	13.2	Sublicensee Insurance. Unless said activities are otherwise covered by Avro Insurance, any Sublicense shall require Sublicensee(s), at the Sublicensee(s) expense, to obtain and maintain liability insurance at a
level commensurate with the Avro Insurance, naming Avro and UHN as additional insured; provided however, that if the Sublicensee is a substantial multi-national entity which has a policy of self-insuring, then Sublicensee may self-insure. Sublicense
agreements shall require Sublicensee(s) to provide to Avro and to UHN a Certificate of Insurance evidencing compliance with this provision prior to the earlier of the first use of the Licensed Technology in humans or first sale of Licensed
Product(s) under any Sublicense. In no event shall the Sublicensee(s) use the Licensed Technology in humans or engage in the sale of Licensed Product(s) under this or any Sublicense agreement prior to the delivery to UHN of the Certificate of
Insurance or an indication of self-insurance, as applicable. The Sublicense shall provide that Sublicensee(s) (at no expense to UHN) shall obtain and maintain from the initial date required by this Section 13.2 until the end of the term of the
Sublicense and an additional period of [***] thereafter, a policy of appropriate liability insurance (or self-insurance, if applicable) at a level commensurate with the Avro Insurance. In the event that Sublicensee does not have the insurance
coverage required by this Section 13.2, Avro shall terminate said Sublicense or otherwise ensure subject to UHN prior approval, that the activities of said Sublicensee are insured by Avro. 


 

	13.3	Qualified Insurance. All insurance policies required in accordance with this Article 13 shall be obtained from an insurance company qualified to offer protection in the jurisdictions where Licensed Technology is
to be exploited or Licensed Product(s) are offered for sale. 

  

	13.4	Notice. Avro shall provide [***] written notice to UHN by registered or certified mail in the event of any modification, cancellation or termination of such insurance policy. 


 

	13.5	Copy of Policy. Avro shall, on written request, provide UHN with a copy of the insurance policy in force at the time of the request and this provision shall survive the termination of this Agreement for a period
of [***]. 

  

	13.6	Incomplete Insurance. In the event Avro does not have the insurance coverage required by this Article 13, or if any portion of the Avro Insurance or other required coverage is cancelled and not immediately
replaced, Avro shall promptly inform UHN and UHN shall be free to terminate this Agreement upon notice to Avro in accordance with Section 11.3.1. 


ARTICLE 14 - DISPUTE RESOLUTION 
  

	14.1	Good Faith Efforts. Except as otherwise stated in this Agreement, the Parties agree to use good faith efforts to resolve amicably among themselves any dispute arising out of or relating to this Agreement.



  
 *** Confidential Treatment
Requested *** 
  
 36 









	14.2	Referral for Resolution. If the Parties are unable to resolve the dispute under Section 14.1 within [***] of written notice of one Party to the other Party of such dispute, the dispute shall be referred to
the Executive Vice President, Research of UHN (or designate) and the CEO (or designate) of Avro for their discussion and resolution for an additional period of [***]. 


 

	14.3	As mandated by Sections 4.6, 11.3.1, 11.3.2, 11.3.3 or 11.5, if a dispute is not resolved pursuant to Section 14.2, and mandatory arbitration is thereafter dictated, such dispute shall be finally settled
under mandatory arbitration (such decision to be final and non-appealable) pursuant to the Rules of Arbitration of the International Chamber of Commerce (“ICC”). The legal place of arbitration
shall be Toronto and the official language of the arbitration shall be English. The arbitration will be heard and determined by three (3) arbitrators who are retired judges or attorneys with at least ten (10) years of relevant experience
in the pharmaceutical and biotechnology industry, each of whom will be impartial and independent. Each Party will appoint one (1) arbitrator and the third (3rd) arbitrator will be selected by the two (2) Party-appointed arbitrators, or,
failing agreement within [***] following appointment of the second arbitrator, by the ICC. The arbitration award so given will be a final and binding determination of the dispute, will be fully enforceable in any court of competent jurisdiction, and
will not include any damages expressly prohibited under Section 6.3.3. Fees, costs and expenses of arbitration are to be divided by the Parties in the following manner: UHN will pay for the arbitrator it chooses, Avro will pay for the
arbitrator it chooses, and the Parties will share payment for the third arbitrator. Except in a proceeding to enforce the results of the arbitration or as otherwise required by Law, neither Party nor any arbitrator may disclose the existence,
content or results of any arbitration hereunder without the prior written consent of both Parties. 

  

	14.4	Interim Protection. This Article 14 shall not prevent a Party from applying to a court of competent jurisdiction for equitable relief or interim protection such as, by way of example, an interim injunction for
breaches of confidentiality pursuant to Article 9. 

 ARTICLE 15 - NOTICE 

 

	15.1	Notice. All notices which are required or permitted to be given hereunder (“Notices”) including judicial payment notices must be in writing. All such Notices must be sent as follows:


 to UHN: 

Attention: 
 Director, Technology
Development & Commercialization 
 UHN Health Network 

101 College Street - Suite 150 

Heritage Building - MaRS Centre 

Toronto, Ontario, Canada M5G 1L7 

to Avro: 
 AvroBio, Inc. 

400 Technology Square, 10th Floor 

Cambridge, MA 02139 
 Attention:
CEO 

  
 *** Confidential Treatment
Requested *** 
  
 37 








 or to such other address as a Party may designate by Notice given in accordance with this Article
15. Any such Notice may be delivered by hand or by overnight courier and will be deemed to have been delivered on the date of delivery. 

ARTICLE 16 - GENERAL 
  

	16.1	Entire Agreement. The Parties acknowledge that this Agreement its Schedules, any SRAs, the Material Transfer Agreement, the Letter Agreement and any other related document required to effect the contemplated
transactions, shall be the entire agreement and understanding of the Parties as to the subject matter of this Agreement, and supersedes all prior discussions, agreements and writings in respect of the subject matter of this Agreement, including,
without limitation the Option Agreement. For the avoidance of doubt, this Agreement does not amend, restate, supplement or otherwise modify any of the terms or conditions of any other agreement between the Parties, including the IL-12 Agreement. The IL-12 Agreement shall remain in full force and effect in accordance with its terms and conditions. 


 

	16.2	General Assurances. The Parties agree to do all such things and to execute such instruments and documents as may be necessary or desirable in order to carry out the provisions and intent of this Agreement.


  

	16.3	Inure to Benefit. This Agreement shall inure to the benefit of and be binding upon the respective Parties and, where the context admits or requires, their respective permitted successors or assigns.


  

	16.4	Assignment. 

  

	 	16.4.1	Avro may assign its rights and obligations under this Agreement to (a) an Affiliate or (b) a Third Party in connection with the merger, consolidation, reorganization, or sale of all or substantially all
of its assets or that portion of its business to which this Agreement relates. 

  

	 	16.4.2	In the event of (a) a merger or acquisition of Avro by a Third Party during the Term or (b) a sale of all or substantially all of Avro’s assets (including this Agreement) relating to the Licensed
Products to a Third Party during the Term (respectively a “License Transfer”), a “License Transfer Fee” shall be payable to UHN equal to [***] percent ([***]%) of proceeds from the License Transfer,
subject to a total cap of License Transfer Fees as between this Agreement and any License Transfer Fee payable under the IL-12 Agreement of [***]. For certainty and clarity, a License Transfer shall exclude
any equity or debt financing (other than, for clarity, in connection with a sale of all or substantially of Avro’s assets (including this Agreement) relating to the Licensed Products to a Third Party), any initial public offering, or any
transaction involving Avro or its Affiliates in which the stockholders of Avro or its Affiliates immediately preceding such transaction retain fifty percent (50%) or more of the outstanding shares, or fifty percent (50%) or more of the outstanding
voting power, respectively, of the ultimate company or entity resulting from such transaction immediately after consummation thereof. 


  
 *** Confidential Treatment
Requested *** 
  
 38 









	 	16.4.3	The License Transfer Fee payable in respect of the License Transfer will be due within [***] of the closing of the License Transfer (or actual receipt of consideration in the event of scheduled payments for the
License Transfer), and will be payable in the same type of consideration (e.g., cash, securities, etc.) received by Avro or its stockholders. The License Transfer Fee shall only apply with respect to the first License Transfer and not with respect
to any subsequent License Transfers. Notwithstanding the foregoing, (sub)licenses, licenses to manufacture, or licenses for distribution relating to Licensed Products or Licensed Technology, or sales of assets, (sub)licenses, licenses to
manufacture, licenses for distribution or other transactions relating to other products, etc. shall not be deemed a License Transfer hereunder. The License Transfer Fee shall be in addition to any distributions due to UHN as a shareholder in Avro.


  

	16.5	No Joint Venture. Each Party is and will remain at all times independent of each other. The Parties are not and shall not be considered to be joint venturers, partners or agents of each other and neither of them
shall have the power to bind or obligate the other except as set forth in this Agreement. The Parties mutually covenant and agree that neither shall they, in any way, incur any contractual or other obligation in the name of the other, nor shall they
have liability for any debts incurred by the other. No representation will be made or acts taken by any of the Parties which could establish any apparent relationship of agency, joint venture, partnership or employment. 


 

	16.6	Waiver. No amendment, supplement or waiver of any provision of this Agreement shall be binding on any Party unless consented to in writing by such Party. No waiver of any provision of this Agreement shall
constitute a waiver of any other provision, nor shall any waiver constitute a continuing waiver unless otherwise expressly provided. Further, no failure or delay by any Party in exercising any right or remedy shall operate as a waiver of such right
or remedy, nor shall any single or partial exercise or waiver of any right or remedy preclude its further exercise or the exercise of any other right or remedy. 

  

	16.7	Joint Preparation. This Agreement shall be deemed to be jointly prepared by the Parties, and any ambiguity herein shall not be construed for or against any single Party. 


 

	16.8	Governing Law. This Agreement shall be governed by the laws of the Province of Ontario and the laws of Canada applicable therein, and shall be treated as an Ontario contract. Subject to Article 14, the Parties
irrevocably and unconditionally submit to the exclusive jurisdiction the courts of Ontario and all courts competent to hear appeals therefrom in connection with any matters arising under this Agreement, except for disputes under Sections
4.6,11.3.1,11.3.2,11.3.3 or 11.5, each of which shall be addressed pursuant to Section 14.3. 

  

	16.9	Severability of Provisions. In the event that any provisions of this Agreement is determined to be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of this
Agreement shall remain in full force and effect without said provision in said jurisdiction and such determination shall not affect the validity or enforceability of such provision or this Agreement in any other jurisdiction. The Parties shall in
good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement. 


  
 *** Confidential Treatment
Requested *** 
  
 39 









	16.10	Force Majeure. In the event that any one of the Parties is prevented from fulfilling any of its obligations herein by acts of God, war, terrorism, strikes, riots, storms, fires, governmental orders or
restrictions or any other cause beyond its control, the payment of royalties or milestones or other required payments, or the applicable pro rata portion thereof, shall be suspended during the full period of any such prevention, but payment of
Royalties, Sublicensing Fee(s), milestones or other required payments which have accrued for payment prior to, during or after such cause shall not be excused. UHN will have the right to immediately terminate this Agreement in the event that Avro is
unable to fulfill its obligations further to this Section 16.10 for a period of [***]. 

  

	16.11	Survival. The termination or expiration of this Agreement shall not relieve the Parties of any obligations accruing prior to such expiration or termination (including any payments accrued and delayed pursuant to
Section 5.7), and any such expiration or termination shall be without prejudice to the rights of either Party against the other Party. Sections 2.3 (last sentence), 4.3, 4.11, 4.12, 4.13, 4.14, 6.3, 11.4, 11.5, 11.6, 12.1, 13.1, and 13.2 and
Articles 1,9, 10, 14, 15 and 16 (excluding Section 16.4.2 and 16.4.3 if License Transfer occurs after expiration or termination) shall remain in force and effect after the expiration or earlier termination of this Agreement until such time as
specifically noted in a particular Section or Article, or the Parties mutually agree to the release of the obligation (in whole or in part) contained therein. 

  

	16.12	Counterparts. This Agreement may be executed in counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Transmission by facsimile, email or
other form of electronic transmission of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart. Alternatively, the Agreement may be exchanged and executed by facsimile or other form
of electronic transmission as a single document. 

 [SIGNATURE PAGE FOLLOWS] 

  
 *** Confidential Treatment
Requested *** 
  
 40 








 The Parties are executing this Agreement so as to be effective on the Effective Date. 

 

			
	 UNIVERSITY HEALTH NETWORK
  

Per: /s/ Bradly G.
Wouters                                        

 Name: Dr. Bradly G. Wouters
 Title: Executive
Vice President Science and Research
	  	 AvroBio, Inc.
  

Per: /s/ Geoff
MacKay                                        

 Name: Geoff MacKay
 Title: President and Chief Executive
Officer



  
 *** Confidential Treatment
Requested *** 
  








 Schedule “A” 

Fabry Know-How 
  

					
	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  		  	
	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]



  
 *** Confidential Treatment
Requested *** 
  









					
	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	
	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]


 [***] 
 [***] 

[***] 
 [***] 

  
 *** Confidential Treatment
Requested *** 
  








 Schedule B 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

  
 *** Confidential Treatment
Requested *** 
  








 Schedule “C” 

Fabry Patents 
 [***] 

[***] 
 [***] 

[***] 

  
 *** Confidential Treatment
Requested *** 
  








 SCHEDULE D 

Licensed SRA IP 
 (as
amended and updated) 

  
 *** Confidential Treatment
Requested *** 
  








 SCHEDULE E 

Optioned Improvement Patent(s) 

(as amended and updated) 

  
 *** Confidential Treatment
Requested ***